How many Ruxolitinib clinical trials are there?

388 Ruxolitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 95 are actively recruiting participants. 138 are marked completed.

Are Ruxolitinib clinical trials recruiting in 2026?

Yes — 95 Ruxolitinib trials are actively recruiting in 2026, with 558 U.S. sites across 41 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ruxolitinib being studied for?

Ruxolitinib is being studied for Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Atopic Dermatitis, Vitiligo and 493 more. The trials are grouped by indication on this page.

What phase is Ruxolitinib in?

Ruxolitinib clinical trials span 14 Phase 4, 53 Phase 3, 158 Phase 2, 69 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ruxolitinib clinical trials?

The lead sponsor across the most Ruxolitinib trials is Incyte Corporation, with 159 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Ruxolitinib Clinical Trials (2026): 388 Studies for Myelofibrosis & Primary Myelofibrosis

Creator: Hipa.ai Research
Published: 2026-06-02T16:39:20.352Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

388 Ruxolitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 207 indications (including Myelofibrosis & Primary Myelofibrosis) and 43,693 total planned enrollment. 53 Phase 3 Ruxolitinib trials and 158 Phase 2, 14 Phase 4 are listed. 110 Ruxolitinib clinical trials are actively recruiting at 558 U.S. sites across 41 states. Most recent activity: NCT06768476 (Mar 2045).

Where to Participate: All Ruxolitinib Trial Sites in the U.S. (558 sites across 41 states)

Every actively recruiting Ruxolitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Clinical Research Center of Alabama	Birmingham35209	NCT06832618	Map
AL	Investigative Site US218	Birmingham35244	NCT06958211	Map
AL	Investigative Site US257	Birmingham35203	NCT06958211	Map
AL	Total Skin And Beauty Dermatology Center	Birmingham35203	NCT07133308	Map
AL	UAB Hospital	Birmingham35233	NCT06479135	Map
AL	University of Alabama	Birmingham35294	NCT04176198	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT05280509	Map
AL	University of Alabama Birmingham	Birmingham35294	NCT06859424	Map
AL	Investigative Site US239	Montgomery36117	NCT06958211	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT06479135	Map
AZ	Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)	Glendale85304	NCT06079879	Map
AZ	Investigative Site US020	Phoenix85008	NCT06959225	Map
AZ	Investigative Site US215	Phoenix85006	NCT06958211	Map
AZ	Investigative Site US261	Phoenix85037	NCT06958211	Map
AZ	Mayo Clinic - Phoenix	Phoenix85054	NCT06479135	Map
AZ	Phoenix Children'S Hospital	Phoenix85016	NCT06548360	Map
AZ	Saguaro Dermatology	Phoenix85008	NCT06832618	Map
AZ	Saguaro Dermatology	Phoenix85008	NCT07049575	Map
AZ	Avacare - Cct Research - Center For Dermatology And Plastic Surgery	Scottsdale85260	NCT07133308	Map
AZ	Investigative Site US033	Scottsdale85259	NCT06959225	Map
AZ	Mayo Clinic in Arizona	Scottsdale85259	NCT03017820	Map
AZ	Investigative Site US054	Tempe85282	NCT06959225	Map
AZ	Banner - University Medicine Multispecialty Services Clinic	Tucson85718	NCT06548360	Map
AZ	Investigative Site US240	Tucson85718	NCT06958211	Map
AZ	The University of Arizona Cancer Center	Tucson85724	NCT04176198	Map
AR	Dermatology Trial Associates	Bryant72022	NCT07133308	Map
AR	Investigative Site US002	Fayetteville72703	NCT06959225	Map
AR	Premier Dermatology Clinical Trials Institute At Northwest Arkansas	Fayetteville72703	NCT06548360	Map
AR	Burke Pharmaceutical Research	Hot Springs71913	NCT06548360	Map
CA	Global Oncology, Inc.	Alhambra91801	NCT03110822	Map
CA	Kern Research Inc.	Bakersfield93301	NCT07133308	Map
CA	Investigative Site US055	Brea92821	NCT06959225	Map
CA	City of Hope	Duarte91010	NCT05371964	Map
CA	City of Hope	Duarte91010	NCT04176198	Map
CA	City of Hope	Duarte91010	NCT06150157	Map
CA	City of Hope	Duarte91010	NCT06859424	Map
CA	City of Hope - Duarte Main Site	Duarte91010	NCT05980806	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06936566	Map
CA	City of Hope Medical Center	Duarte91010	NCT06034002	Map
CA	City of Hope Medical Center	Duarte91010	NCT06128070	Map
CA	City of Hope Medical Center	Duarte91010	NCT07025538	Map
CA	City of Hope Medical Center	Duarte91010	NCT07278856	Map
CA	California Cancer Associates for Research & Excellence (cCARE)	Encinitas92024	NCT03110822	Map
CA	Investigative Site US262	Encino91436	NCT06958211	Map
CA	First Oc Dermatology	Fountain Valley92708	NCT07049575	Map
CA	Investigative Site US222	Fountain Valley92708	NCT06958211	Map
CA	Center For Dermatology Clinical Research Inc.	Fremont94538	NCT07133308	Map
CA	Los Angeles Cancer Network ( Site 3491)	Glendale91206	NCT06079879	Map
CA	Axon Clinical Research	Inglewood90301	NCT06548360	Map
CA	City of Hope	Irvine92618	NCT05371964	Map
CA	University of California Irvine	Irvine92697	NCT06548360	Map
CA	University of California, Irvine	Irvine92697	NCT06160791	Map
CA	UC San Diego Moores Cancer Center	La Jolla92037	NCT06479135	Map
CA	University of California, San Diego Moores Cancer Center	La Jolla92093	NCT07219576	Map
CA	Investigative Site US004	Laguna Niguel92677	NCT06959225	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT06548360	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT07133308	Map
CA	Investigative Site US007	Los Angeles90033	NCT06959225	Map
CA	Investigative Site US211	Los Angeles90045	NCT06958211	Map
CA	Investigative Site US237	Los Angeles90056	NCT06958211	Map
CA	La Universal Research Center, Inc	Los Angeles90057	NCT06548360	Map
CA	UCLA Hematology/Oncology Clinic - Los Angeles	Los Angeles90095	NCT06479135	Map
CA	University of Southern California	Los Angeles90033	NCT04176198	Map
CA	Vitiligo & Pigmentation Institute of Southern California	Los Angeles90036-5609	NCT06548360	Map
CA	Hoag Family Cancer Institute	Newport Beach92663	NCT04176198	Map
CA	Amicis Research Center Valencia	Northridge91324	NCT07049575	Map
CA	Investigative Site US234	Northridge91325	NCT06958211	Map
CA	Palmtree Clinical Research	Palm Springs92262	NCT07133308	Map
CA	Stanford	Palo Alto94304	NCT06859424	Map
CA	Stanford Cancer Center	Palo Alto94304	NCT06615050	Map
CA	Stanford Cancer Institute	Palo Alto94304	NCT06034002	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT03801434	Map
CA	Stanford School of Medicine	Palo Alto94304	NCT06548360	Map
CA	Empire Clinical Research	Pomona91767	NCT06548360	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06160791	Map
CA	Investigative Site US013	San Diego92103	NCT06959225	Map
CA	Investigative Site US038	San Diego92121	NCT06959225	Map
CA	Investigative Site US060	San Diego92120	NCT06959225	Map
CA	Paradigm Clinical Research - San Diego	San Diego92108	NCT07133308	Map
CA	Rady Children'S Hospital-San Diego	San Diego92123	NCT06548360	Map
CA	Scripps Health, Prebys Cancer Center	San Diego92103	NCT06479135	Map
CA	University of California San Francisco	San Francisco94158	NCT06615050	Map
CA	University of California, San Francisco	San Francisco94143	NCT06160791	Map
CA	Investigative Site US250	Santa Ana92706	NCT06958211	Map
CA	Stanford Cancer Institute ( Site 0107)	Stanford94305-5826	NCT06079879	Map
CA	Clinical Trials Research Institute	Thousand Oaks91320	NCT07049575	Map
CA	The Lundquist Institute ( Site 3423)	Torrance90502	NCT06079879	Map
CA	The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Torrance90502	NCT06479135	Map
CA	Wellness Oncology and Hematology	West Hills91307	NCT03110822	Map
CA	Berenson Cancer Center	West Hollywood90069	NCT06209606	Map
CA	Berenson Cancer Center	West Hollywood90069	NCT06225310	Map
CA	James R. Berenson M.D. Inc.	West Hollywood90069	NCT03110822	Map
CO	Children'S Hospital Colorado	Aurora80045	NCT06548360	Map
CO	Investigative Site US059	Aurora80045	NCT06959225	Map
CO	Rocky Mountain Cancer Centers - Aurora	Aurora80012	NCT06479135	Map
CO	UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center	Aurora80045	NCT06150157	Map
CO	University of Colorado Anschutz Medical Campus ( Site 3425)	Aurora80045	NCT06079879	Map
CO	Clarity Dermatology	Castle Rock80109	NCT07049575	Map
CO	Investigative Site US244	Castle Rock80109	NCT06958211	Map
CO	Blood Cancer Center	Denver80218	NCT04176198	Map
CO	Colorado Medical Research Center	Denver80210	NCT07133308	Map
CO	National Jewish Health	Denver80206	NCT06832618	Map
CO	Paradigm Clinical Research - Wheat Ridge	Wheat Ridge80033	NCT07133308	Map
CO	Paradigm Clinical Research Centers, Inc.	Wheat Ridge80033	NCT06548360	Map
CT	Investigative Site US252	Cromwell06416	NCT06958211	Map
CT	Yale School of Medicine	New Haven06510	NCT04176198	Map
DE	Medical Oncology Hematology Consultants, PA	Newark19713	NCT06479135	Map
DC	MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center	Washington D.C.20007	NCT06479135	Map
FL	Investigative Site US208	Boca Raton33486	NCT06958211	Map
FL	Skin Care Research, Llc	Boca Raton33486	NCT06548360	Map
FL	Encore Medical Research, Llc Boynton Beach	Boynton Beach33436	NCT06548360	Map
FL	Investigative Site US045	Boynton Beach33437	NCT06959225	Map
FL	University of Miami	Coral Gables33146	NCT05371964	Map
FL	D&H Doral Research Center	Doral33122	NCT07133308	Map
FL	Investigative Site US028	Fort Myers33912	NCT06959225	Map
FL	Investigative Site US203	Hialeah33012-3618	NCT06958211	Map
FL	Encore Medical Research, Llc Hollywood	Hollywood33024	NCT06832618	Map
FL	Skin Care Research, Llc	Hollywood33201	NCT06548360	Map
FL	Skin Care Research, Llc - Hollywood	Hollywood33021	NCT07133308	Map
FL	Cancer Specialists, LLC	Jacksonville32256	NCT03110822	Map
FL	Investigative Site US258	Jacksonville32216	NCT06958211	Map
FL	Mayo Clinic - Jacksonville	Jacksonville32224	NCT06479135	Map
FL	Solutions Through Advanced Research, Inc	Jacksonville32256	NCT06548360	Map
FL	Ilumina Medical Research Llc	Kissimmee34744	NCT07133308	Map
FL	Investigative Site US206	Maitland32751	NCT06958211	Map
FL	Advance Research Center, Llc	Miami33183	NCT07133308	Map
FL	All X Ray Diagnostic Services Corp	Miami33126	NCT07133308	Map
FL	Baptist Health - Miami Cancer Institute	Miami33176	NCT04176198	Map
FL	Florida International Medical Research	Miami33134	NCT07133308	Map
FL	Florida Pharmaceutical Research And Associates, Inc.	Miami33143	NCT07133308	Map
FL	Investigative Site US016	Miami33142	NCT06959225	Map
FL	Investigative Site US202	Miami33173	NCT06958211	Map
FL	Investigative Site US223	Miami33136	NCT06958211	Map
FL	Investigative Site US241	Miami33147	NCT06958211	Map
FL	L&C Professional Medical Research Institute	Miami33144	NCT07133308	Map
FL	Miami Cancer Institute at Baptist Health, Inc.	Miami33176	NCT06991101	Map
FL	Millennium Medical Research Llc	Miami33126	NCT07133308	Map
FL	Nicklaus Children'S Hospital	Miami33155	NCT06548360	Map
FL	Pediatric Skin Research Llc	Miami33146	NCT06548360	Map
FL	Pediatric Skin Research Llc	Miami33156	NCT07133308	Map
FL	Univ of Miami - Sylvester Comprehensive Cancer Center	Miami33136	NCT06660355	Map
FL	University of Miami	Miami33136	NCT04176198	Map
FL	University of Miami	Miami33136	NCT06479135	Map
FL	University of Miami	Miami33136	NCT06615050	Map
FL	University of Miami	Miami33136	NCT06859424	Map
FL	University of Miami Health System	Miami33136	NCT06034002	Map
FL	Valencia Medical & Research Center	Miami33174	NCT07133308	Map
FL	Barroso Medical Services Llc	Miami Lakes33014	NCT07133308	Map
FL	AdventHealth Cancer Institute	Orlando32803	NCT06479135	Map
FL	Nexus Research Llc	Pompano Beach33063	NCT07133308	Map
FL	International Clinical Research Tennessee Llc	Sanford32771	NCT07049575	Map
FL	International Clinical Research Us Llc - Sanford	Sanford32771	NCT07133308	Map
FL	Investigative Site US027	Sanford32771	NCT06959225	Map
FL	Investigative Site US057	Sweetwater33172	NCT06959225	Map
FL	Lenus Research & Medical Group Llc.	Sweetwater33172	NCT07133308	Map
FL	Lenus Research Medical Group, Llc	Sweetwater33172	NCT07049575	Map
FL	Dh Tamarac Research Center Etna Medical Center Emc	Tamarac33321	NCT06548360	Map
FL	H. Lee Moffitt Cancer Center and Research Institute, Inc.	Tampa33612	NCT05371964	Map
FL	Investigative Site US029	Tampa33609	NCT06959225	Map
FL	Investigative Site US214	Tampa33609	NCT06958211	Map
FL	Investigative Site US247	Tampa33612	NCT06958211	Map
FL	Moffit Cancer center	Tampa33612	NCT06150157	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06479135	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06615050	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06660355	Map
FL	Trueblue Clinical Research	Tampa33609	NCT07049575	Map
FL	Usf Health Morsani Center For Advanced Healthcare	Tampa33612	NCT06548360	Map
GA	Blood and Marrow Transplant Group of Georgia	Atlanta30342	NCT06615050	Map
GA	Children's Healthcare of Atlanta	Atlanta30329	NCT07252050	Map
GA	Emory University	Atlanta30322	NCT04176198	Map
GA	Emory University	Atlanta30322	NCT06150157	Map
GA	Investigative Site US053	Atlanta30331	NCT06959225	Map
GA	Winship Cancer Institute, Emory University	Atlanta30322	NCT06936566	Map
GA	Investigative Site US231	Columbus31904	NCT06958211	Map
GA	Lane Dermatology and Dermatologic Surgery	Columbus31904	NCT07049575	Map
GA	Cleaver Medical Group	Cumming30040	NCT06548360	Map
GA	Cleaver Medical Group	Cumming30040	NCT06832618	Map
GA	Cleaver Medical Group Dermatology	Cumming30040	NCT07133308	Map
GA	Skin Care Physicians Of Georgia	Macon31217	NCT07133308	Map
GA	Investigative Site US019	Marietta30060	NCT06959225	Map
GA	Advanced Medical Research Pc	Sandy Springs30328	NCT06548360	Map
GA	Investigative Site US225	Sandy Springs30328	NCT06958211	Map
GA	Georgia Skin & Cancer Clinic	Savannah31419	NCT07133308	Map
ID	Asr, Llc	Boise83702	NCT07133308	Map
ID	Treasure Valley Medical Research	Boise83706	NCT06548360	Map
ID	Treasure Valley Medical Research	Boise83706	NCT06832618	Map
IL	Denova Research	Chicago60611	NCT07133308	Map
IL	Illinois Dermatology Institute the Chicago Loop	Chicago60602	NCT06548360	Map
IL	Investigative Site US026	Chicago60657	NCT06959225	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT06548360	Map
IL	Rush University Medical Center	Chicago60612	NCT06548360	Map
IL	University of Chicago	Chicago60637	NCT04176198	Map
IL	University of Chicago Medical Center	Chicago60637	NCT03571321	Map
IL	University of Chicago Medicine Comprehensive Cancer Center	Chicago60637	NCT06291987	Map
IL	Sneeze Wheeze and Itch Associates Llc	Normal61761	NCT06832618	Map
IL	Investigative Site US207	Skokie60077	NCT06958211	Map
IL	Northshore University Healthsystem	Skokie60077	NCT06548360	Map
IN	Ds Research - Indiana	Clarksville47129	NCT07133308	Map
IN	Investigative Site US049	Clarksville47129	NCT06959225	Map
IN	Dawes Fretzin Clinical Research Group Llc.	Indianapolis46250	NCT07133308	Map
IN	Indiana University Cancer Center	Indianapolis46202	NCT06615050	Map
IN	Indiana University School of Medicine	Indianapolis46202	NCT06548360	Map
IN	Investigative Site US205	Plainfield46168	NCT06958211	Map
IN	Investigative Site US052	West Lafayette47906	NCT06959225	Map
IN	Options Research Group, Llc	West Lafayette47906	NCT07049575	Map
IA	Mission Cancer + Blood	Des Moines50314	NCT06479135	Map
KS	Kansas University Medical Center	Fairway66205	NCT06936566	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06660355	Map
KS	University of Kansas Hospital Authority	Kansas City66160	NCT06615050	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06034002	Map
KS	University of Kansas Cancer Center - Westwood	Westwood66205	NCT06479135	Map
KS	University of Kansas Medical Center	Westwood66205	NCT06859424	Map
KY	Equity Medical, Llc	Bowling Green42104	NCT07049575	Map
KY	Investigative Site US001	Bowling Green42104	NCT06959225	Map
KY	Ds Research - Kentucky	Louisville40241	NCT07133308	Map
KY	Investigative Site US022	Louisville40241	NCT06959225	Map
KY	Norton Cancer Institute	Louisville40207	NCT06479135	Map
LA	Delricht Research	Baton Rouge70809	NCT07049575	Map
LA	Investigative Site US050	Baton Rouge70809	NCT06959225	Map
LA	Mary Bird Perkins Cancer Center	Baton Rouge70809	NCT06479135	Map
LA	Investigative Site US264	Lake Charles70601	NCT06958211	Map
LA	Investigative Site US266	New Orleans70115	NCT06958211	Map
LA	Tulane University Health Sciences Center	New Orleans70112	NCT06548360	Map
MD	Johns Hopkins Hospital	Baltimore21287	NCT06034002	Map
MD	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore21231	NCT06479135	Map
MD	University of Maryland	Baltimore21201	NCT04176198	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT05398809	Map
MD	The Center for Cancer and Blood Disorders	Bethesda20817	NCT06479135	Map
MD	Maryland Oncology Hematology - Independent of SCRI/ US Oncology	Columbia21044	NCT05980806	Map
MD	Investigative Site US254	Gambrills21054	NCT06958211	Map
MD	Investigative Site US046	Glenn Dale20769	NCT06959225	Map
MD	Investigative Site US201	Marriottsville21104	NCT06958211	Map
MD	Raven Clinical Research	Marriottsville21104	NCT06832618	Map
MD	Dermatology Associates Pc	Rockville20850	NCT06548360	Map
MD	U.S. Dermatology Partners - Rockville	Rockville20850	NCT07133308	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT04644211	Map
MA	Dana Farber Cancer Institute	Boston02115	NCT05010005	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06034002	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06479135	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06615050	Map
MA	Dana Farber Cancer Institute	Boston02115	NCT06936566	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05592015	Map
MA	Dana-Farber Cancer Institute	Boston02446	NCT06859424	Map
MA	Investigative Site US003	Boston02115	NCT06959225	Map
MA	Investigative Site US030	Boston02215	NCT06959225	Map
MA	Massachusetts General Hospital	Boston02115	NCT04644211	Map
MA	Massachusetts General Hospital	Boston02114	NCT04176198	Map
MA	Massachusetts General Hospital	Boston02114	NCT06548360	Map
MA	Massachusetts General Hospital	Boston02114	NCT06615050	Map
MA	Massachusetts General Hospital	Boston02114	NCT06936566	Map
MA	Massachusetts General Hospital (Data Collection Only)	Boston02114	NCT06773195	Map
MA	Tufts Medical Center ( Site 3408)	Boston02111	NCT06079879	Map
MA	Massachusetts General North Shore Cancer Center	Danvers01923	NCT04644211	Map
MA	Investigative Site US253	Milford01757	NCT06958211	Map
MA	Investigative Site US227	Needham02492	NCT06958211	Map
MA	Investigative Site US010	Quincy02169	NCT06959225	Map
MI	Investigative Site US238	Ann Arbor48103	NCT06958211	Map
MI	University of Michigan	Ann Arbor48109	NCT04176198	Map
MI	University of Michigan	Ann Arbor48109	NCT06150157	Map
MI	University of Michigan	Ann Arbor48109	NCT06615050	Map
MI	University of Michigan ( Site 0008)	Ann Arbor48109	NCT06079879	Map
MI	University of Michigan Comprehensive Cancer Center	Ann Arbor48109	NCT06616155	Map
MI	University of Michigan Hospital	Ann Arbor48109	NCT06479135	Map
MI	Investigative Site US230	Auburn Hills48326	NCT06958211	Map
MI	Oakland Hills Dermatology	Auburn Hills48326	NCT07133308	Map
MI	Henry Ford Cancer Institute - Brigitte Harris Cancer Pavilion	Detroit48202	NCT06479135	Map
MI	Henry Ford Health System	Detroit48202	NCT06832618	Map
MI	Henry Ford Hospital	Detroit48202	NCT06615050	Map
MI	Henry Ford Hospital ( Site 3413)	Detroit48202	NCT06079879	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06615050	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06859424	Map
MI	Revival Research Institute, Llc - Troy, Mi	Troy48084	NCT07133308	Map
MI	Revival Research Institute, Llc Troy	Troy48084	NCT07049575	Map
MN	Axis Clinicals	Dilworth56529	NCT07588139	Map
MN	Investigative Site US006	Minneapolis55455	NCT06959225	Map
MN	University of Minnesota	Minneapolis55455	NCT03681561	Map
MN	University of Minnesota	Minneapolis55455	NCT04176198	Map
MN	Investigative Site US021	New Brighton55112	NCT06959225	Map
MN	Mayo Clinic	Rochester55905	NCT06936566	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT03017820	Map
MO	Red River Research Partners	Bolivar65613	NCT06832618	Map
MO	Red River Research Partners	Bolivar65613	NCT07049575	Map
MO	Investigative Site US036	Saint Joseph64506	NCT06959225	Map
MO	Medisearch Clinical Trials	Saint Joseph64506	NCT06832618	Map
MO	Medisearch Clinical Trials	Saint Joseph64506	NCT07133308	Map
MO	Investigative Site US251	St Louis63110-1010	NCT06958211	Map
MO	Washington University	St Louis63110	NCT06615050	Map
MO	Washington University of Medicine	St Louis63110	NCT04176198	Map
MO	Washington University School of Medicine	St Louis63110	NCT06008808	Map
MO	Washington University School of Medicine	St Louis63108	NCT06034002	Map
MO	Investigative Site US271	Wildwood63040	NCT06958211	Map
MT	Boeson Research	Missoula59804	NCT06548360	Map
MT	Boeson Research Mso	Missoula59804	NCT07133308	Map
MT	Investigative Site US212	Missoula59804	NCT06958211	Map
NE	Nebraska Hematology - Oncology, P.C.	Lincoln68506	NCT06479135	Map
NE	Skin Specialists Pc the Advanced Skin Research Center	Omaha68144	NCT06548360	Map
NE	Skin Specialists, Pc	Omaha68144	NCT07133308	Map
NV	Mohtaseb Cancer Center and Blood Disorders	Henderson86442	NCT06479135	Map
NV	Investigative Site US216	Las Vegas89145	NCT06958211	Map
NV	Optum Care Cancer Center ( Site 3497)	Las Vegas89102	NCT06079879	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT02974647	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT05714072	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT05010005	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT06773195	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07359859	Map
NJ	Summit Medical Group	Berkeley Heights07922	NCT07357727	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT06479135	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT04176198	Map
NJ	Investigative Site US235	Hoboken07030	NCT06958211	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT05714072	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT02974647	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT05010005	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT06773195	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT07359859	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT05714072	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT05010005	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT06773195	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT07359859	Map
NJ	Schweiger Dermatology & Allergy - Verona	Verona07044	NCT07133308	Map
NM	Investigative Site US217	Albuquerque87102	NCT06958211	Map
NM	The University of New Mexico Unm Health Sciences Center Hsc	Albuquerque87102	NCT06548360	Map
NY	Brookdale University Hospital and Medical Center	Brooklyn11212	NCT06479135	Map
NY	Investigative Site US219	Brooklyn11203	NCT06958211	Map
NY	Suny Downstate Medical Center	Brooklyn11203	NCT06548360	Map
NY	Roswell Park Cancer Institute ( Site 3421)	Buffalo14263	NCT06079879	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT02974647	Map
NY	Memorial Sloan Kettering Commack (Limited Protocol Activities)	Commack11725	NCT05010005	Map
NY	Memorial Sloan Kettering Suffolk - Commack	Commack11725	NCT05714072	Map
NY	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT06773195	Map
NY	Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)	Commack11725	NCT07359859	Map
NY	Investigative Site US246	Elmhurst11373	NCT06958211	Map
NY	Investigative Site US269	Fairport14450	NCT06958211	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT02974647	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT05714072	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT05010005	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT06773195	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT07359859	Map
NY	Cayuga Cancer Center	Ithaca14850	NCT06479135	Map
NY	Investigative Site US213	Kew Gardens11415	NCT06958211	Map
NY	Northwell Health, R.J. Zuckerberg Cancer Center	Lake Success11042	NCT06479135	Map
NY	Investigative Site US034	New City10956	NCT06959225	Map
NY	Columbia University Irving Medical Center	New York10032	NCT07283822	Map
NY	Dr Bobby Buka, Md Greenwich Village	New York10012-1354	NCT07049575	Map
NY	Equity Medical, Llc	New York10023	NCT06548360	Map
NY	Equity Medical, Llc	New York10019	NCT07049575	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT05371964	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT04176198	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06936566	Map
NY	Icahn School of Medicine At Mount Sinai	New York10029	NCT06034002	Map
NY	ICAHN School of Medicine at Mount Sinai	New York10029-6574	NCT06479135	Map
NY	Investigative Site US017	New York10023	NCT06959225	Map
NY	Investigative Site US018	New York10003	NCT06959225	Map
NY	Investigative Site US242	New York10075	NCT06958211	Map
NY	Memorial Sloan Kettering	New York10065	NCT06615050	Map
NY	Memorial Sloan Kettering	New York10065	NCT06859424	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT02974647	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05592015	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05714072	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04176198	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05010005	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06034002	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06150157	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06773195	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07359859	Map
NY	Mount Sinai Doctors	New York10028-3135	NCT06548360	Map
NY	Mount Sinai Hospital	New York10029	NCT06615050	Map
NY	The Dermatology Specialists Greenwich	New York10012	NCT06548360	Map
NY	Weill Cornell Medical Center	New York10065	NCT04176198	Map
NY	Weill Cornell Medicine NewYork-Presbyterian	New York10021	NCT05980806	Map
NY	Investigative Site US023	Rochester14623	NCT06959225	Map
NY	Investigative Site US245	Rochester14620	NCT06958211	Map
NY	Skin Search of Rochester	Rochester14623	NCT06548360	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14609	NCT04061421	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activites)	Rockville Centre11553	NCT07359859	Map
NY	Montefiore Cancer Center	The Bronx10461	NCT04176198	Map
NY	Montefiore Einstein Comprehensive Cancer Center	The Bronx10467	NCT06479135	Map
NY	Montefiore Medical Center	The Bronx10467	NCT06150157	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT02974647	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT05714072	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT05010005	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT06773195	Map
NY	Vitality Clinical Trials	Woodbury11797	NCT07133308	Map
NC	Revival Research Institute, Llc - Cary, Nc	Cary27511	NCT07133308	Map
NC	Investigative Site US014	Chapel Hill27516	NCT06959225	Map
NC	University of North Carolina	Chapel Hill27514	NCT06859424	Map
NC	University of North Carolina At Chapel Hill	Chapel Hill27514	NCT06615050	Map
NC	Medical University of South Carolina (MUSC)	Charleston29425-8900	NCT06479135	Map
NC	Atrium Health Levine Cancer Institute	Charlotte28204	NCT06479135	Map
NC	Darst Dermatology	Charlotte28277	NCT07133308	Map
NC	Levine Cancer Institute	Charlotte28204	NCT06150157	Map
NC	Levine Cancer Institute	Charlotte28204	NCT06615050	Map
NC	Duke	Durham27710	NCT06233110	Map
NC	Duke Cancer Institute	Durham27710	NCT04176198	Map
NC	Duke University	Durham27705	NCT05980806	Map
NC	Duke University Health System (DUHS) ( Site 0016)	Durham27710	NCT06079879	Map
NC	Duke University Medical Center	Durham27710	NCT06479135	Map
NC	Duke University Medical Center	Durham27705	NCT06615050	Map
NC	Investigative Site US259	Huntersville28078	NCT06958211	Map
NC	Syneos Health (remote site)	Morrisville27560	NCT06259669	Map
NC	Syneos Health (remote site)	Morrisville27560	NCT06627335	Map
NC	Regional Medical Oncology Center	Wilson27893	NCT06479135	Map
NC	Atrium Health Wake Forest Baptist	Winston-Salem27157	NCT06479135	Map
NC	Investigative Site US263	Winston-Salem27104	NCT06958211	Map
NC	Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)	Winston-Salem27157	NCT06079879	Map
NC	Wake Forest Baptist Medical Center	Winston-Salem27157	NCT06034002	Map
ND	Investigative Site US025	Fargo58103	NCT06959225	Map
ND	Red River Research Partners	Fargo58103	NCT06548360	Map
ND	Red River Research Partners	Fargo58103	NCT07049575	Map
OH	Investigative Site US015	Bexley43209	NCT06959225	Map
OH	Gabrail Cancer Center	Canton44718	NCT05280509	Map
OH	Gabrail Cancer Center	Canton44718	NCT06479135	Map
OH	Investigative Site US044	Cincinnati45219	NCT06959225	Map
OH	University of Cincinnati (UC)	Cincinnati45267	NCT05280509	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT06479135	Map
OH	Cleveland Clinic	Cleveland44195	NCT05980806	Map
OH	Cleveland Clinic	Cleveland44195	NCT06034002	Map
OH	Cleveland Clinic	Cleveland44195	NCT06479135	Map
OH	Cleveland Clinic	Cleveland44195	NCT06615050	Map
OH	Cleveland Clinic	Cleveland44195	NCT06857240	Map
OH	Cleveland Clinic Cancer Center at Fairview Hospital	Cleveland44111	NCT06479135	Map
OH	Investigative Site US228	Cleveland44124	NCT06958211	Map
OH	Centricity Research Columbus	Columbus43213	NCT07049575	Map
OH	Investigative Site US008	Columbus43230	NCT06959225	Map
OH	Investigative Site US243	Columbus43213	NCT06958211	Map
OH	Investigative Site US249	Columbus43213	NCT06958211	Map
OH	Ohio State University	Columbus43210	NCT04176198	Map
OH	Ohio State University	Columbus43210	NCT06615050	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05592015	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03681561	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07249346	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07356245	Map
OH	Independence Family Health Center - Cleveland Clinic	Independence44131	NCT06479135	Map
OH	Dermatologists Of Southwest Ohio	Mason45040	NCT07133308	Map
OH	Investigative Site US031	Mason45040	NCT06959225	Map
OH	Hillcrest Hospital - Cleveland Clinic	Mayfield Heights44124	NCT06479135	Map
OK	Investigative Site US048	Oklahoma City73118	NCT06959225	Map
OK	Unity Clinical Research	Oklahoma City73118	NCT07049575	Map
OR	Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000)	Eugene97401	NCT06079879	Map
OR	Willamette Valley Cancer Institute and Research Center	Eugene97401	NCT06479135	Map
OR	Investigative Site US204	Portland97201	NCT06958211	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT03874052	Map
OR	Oregon Health & Science University	Portland97239	NCT06615050	Map
OR	Oregon Health & Science University	Portland97239	NCT06859424	Map
OR	Oregon Health Sciences University	Portland97239	NCT04061421	Map
PA	Abramson Cancer Center of the University of Pennsylvania	Philadelphia19104	NCT06479135	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT07464951	Map
PA	Investigative Site US056	Philadelphia19107	NCT06959225	Map
PA	Paddington Testing Co Inc	Philadelphia19103	NCT07049575	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06150157	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06615050	Map
PA	University of Pennsylvania	Philadelphia19104	NCT07085039	Map
PA	West Penn Hospital	Pittsburgh15224	NCT06479135	Map
PA	Dermatology Associates Of Plymouth Meeting	Plymouth Meeting19462	NCT07133308	Map
PA	Investigative Site US226	Plymouth Meeting19462	NCT06958211	Map
SC	Investigative Site US256	Bluffton29910	NCT06958211	Map
SC	Investigative Site US024	Charleston29425	NCT06959225	Map
SC	Medical University of South Carolina	Charleston29425	NCT04176198	Map
SC	Medical University of South Carolina	Charleston29425	NCT06548360	Map
SC	Medical University of South Carolina	Charleston29425	NCT06615050	Map
SC	Medical University of South Carolina-Hollings Cancer Center ( Site 3426)	Charleston29425	NCT06079879	Map
SC	Columbia Dermatology	Columbia29212	NCT06548360	Map
SC	Tribe Clinical Research, Llc	Greenville29607	NCT07133308	Map
SC	Investigative Site US267	Mt. Pleasant29464	NCT06958211	Map
SC	Investigative Site US041	Myrtle Beach29788	NCT06959225	Map
TN	Tennessee Oncology	Chattanooga37404	NCT06479135	Map
TN	Investigative Site US047	Nashville37215	NCT06959225	Map
TN	Sarah Cannon	Nashville37203	NCT06615050	Map
TN	Sarah Cannon Cancer Institute	Nashville37203	NCT06150157	Map
TN	Tennessee Oncology	Nashville37203	NCT06479135	Map
TN	Tri-Star Centennial Medical Center	Nashville37203	NCT04176198	Map
TN	Vanderbilt Medical Center	Nashville37232	NCT06615050	Map
TN	Vanderbilt University	Nashville37232	NCT04176198	Map
TN	Vanderbilt University	Nashville37235	NCT06936566	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06034002	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06479135	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT04061421	Map
TN	Delricht Research - Smyrna	Smyrna37167	NCT07133308	Map
TX	Investigative Site US255	Austin78759	NCT06958211	Map
TX	The University of Texas Health Science Center At Houston	Bellaire77401	NCT06548360	Map
TX	Investigative Site US260	Cypress77429	NCT06958211	Map
TX	Baylor University Medical Center, Baylor Charles A Sammons Cancer Center	Dallas75246	NCT06008275	Map
TX	Dermatology Treatment And Research Center - Dallas	Dallas75230	NCT07133308	Map
TX	Investigative Site US062	Dallas75390	NCT06959225	Map
TX	UT - SouthWestern	Dallas75390	NCT06479135	Map
TX	3A Research Llc West Location	El Paso79902	NCT06548360	Map
TX	Investigative Site US035	El Paso79902	NCT06959225	Map
TX	Investigative Site US032	Frisco75033	NCT06959225	Map
TX	North Texas Center For Clinical Research	Frisco75034	NCT07133308	Map
TX	Reveal Research Institute	Frisco75033	NCT06548360	Map
TX	Acrc Trials	Grapevine07605	NCT06548360	Map
TX	Baylor College of Medicine	Houston77030	NCT06615050	Map
TX	M D Anderson Cancer Center	Houston77030	NCT04744116	Map
TX	MD Anderson	Houston77030	NCT05980806	Map
TX	MD Anderson	Houston77030	NCT06859424	Map
TX	Md Anderson Cancer Center	Houston77030	NCT06034002	Map
TX	MD Anderson Cancer Center	Houston77054	NCT04176198	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06150157	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06327100	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06345495	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06936566	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07032727	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06973668	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT07128381	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT05280509	Map
TX	U.T. MD Anderson Cancer Center	Houston77030	NCT06479135	Map
TX	Us Dermatology Partners Longview	Longview75601	NCT06548360	Map
TX	Austin Institute For Clinical Research Inc.	Pflugerville78660	NCT07133308	Map
TX	Investigative Site US012	Plano75025	NCT06959225	Map
TX	Investigative Site US270	Prosper75078	NCT06958211	Map
TX	Investigative Site US011	San Antonio78213	NCT06959225	Map
TX	Texas Dermatology and Laser Specialists	San Antonio78218	NCT06548360	Map
TX	Texas Dermatology And Laser Specialists	San Antonio78218	NCT07133308	Map
TX	The University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06479135	Map
TX	Investigative Site US232	Sugar Land77479	NCT06958211	Map
UT	Investigative Site US037	Murray84107	NCT06959225	Map
UT	University of Utah Midvalley Dermatology	Murray84107	NCT06548360	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT05980806	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT04176198	Map
UT	University of Utah, Huntsman Cancer Institute	Salt Lake City84112	NCT06479135	Map
UT	Jordan Valley Dermatology	South Jordan84095	NCT07133308	Map
UT	Jordan Valley Dermatology Center	South Jordan84095	NCT06548360	Map
UT	Avacare - Cct Research - Springville Dermatology	Springville84663	NCT07133308	Map
VA	Investigative Site US248	Arlington22206	NCT06958211	Map
VA	University of Virginia	Charlottesville22903	NCT06859424	Map
VA	University of Virginia ( Site 3422)	Charlottesville22908	NCT06079879	Map
VA	University of Virginia Cancer Center	Charlottesville22903	NCT04176198	Map
VA	University of Virginia Comprehensive Cancer Center	Charlottesville22908	NCT06660355	Map
VA	Investigative Site US209	Danville24541	NCT06958211	Map
VA	Investigative Site US229	Norfolk23502	NCT06958211	Map
VA	VCU Health Adult Outpatient Pavillion ( Site 3416)	Richmond23219	NCT06079879	Map
VA	VCU Medical Center	Richmond23298	NCT06479135	Map
VA	Virginia Cancer Institute	Richmond23229	NCT06479135	Map
VA	Virginia Commonwealth University	Richmond23219	NCT06660355	Map
VA	Virginia Commonwealth University, North Hospital	Richmond23298	NCT06615050	Map
VA	Virginia Oncology Associates - Virginia Beach	Virginia Beach23456	NCT06479135	Map
WA	National Eagle Research, Llc	Lynnwood98036	NCT07133308	Map
WA	Frontier Dermatology	Mill Creek98012	NCT06548360	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT04282187	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT07228624	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT05371964	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06859424	Map
WA	Fred Hutchinson Cancer Centre	Seattle98109	NCT06479135	Map
WA	Fred Hutchinson Cancer Research Center	Seattle98109	NCT06615050	Map
WA	Fred Hutchinson Cancer Research Center	Seattle98109	NCT06936566	Map
WA	Investigative Site US058	Seattle98195	NCT06959225	Map
WA	Investigative Site US265	Seattle98105	NCT06958211	Map
WA	Seattle Children'S Hospital	Seattle98105	NCT06548360	Map
WA	University of Washington - Fred Hutchinson Cancer Center	Seattle98109	NCT04176198	Map
WA	Dermatology Specialists of Spokane	Spokane99202	NCT06548360	Map
WA	Investigative Site US224	Spokane99202	NCT06958211	Map
WA	Northwest Medical Specialties, PLLC - Tacoma	Tacoma98405	NCT06479135	Map
WI	University of Wisconsin	Madison53705	NCT03681561	Map
WI	University of Wisconsin	Madison53705	NCT06615050	Map
WI	Investigative Site US210	Milwaukee53226	NCT06958211	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06548360	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06615050	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06832618	Map
WI	Sheboygan Cancer & Blood Specialists	Sheboygan53081	NCT06479135	Map

Ruxolitinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	approved for marketing	no longer available	available	Total
Early P1	3	1				1						5
P1	20	9		25	9	1	4	1				69
P1/P2	11	5		20	9	3	3	7				58
P2	38	19	1	66	23	3	1	7				158
P2/P3	2	1			2	1	1					7
P3	12	3		23	7	2	3	3				53
P4	3	1		1	1		3	5				14
N/A	5	1		3	1	2		5	2	4	1	24

Recruiting Ruxolitinib clinical trials (110)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT04644211	Ruxolitinib in Thrombocythemia and Polycythemia Vera	P2	Essential Thrombocythemia	60	Mar 2022
NCT06259669	OPERA-1Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population	—	Pregnancy Related	958	Sep 2023
NCT07128381	MFPhase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)	P1/P2	Myelofibrosis (MF)	66	Jan 2026
NCT07297914	FORUM2Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL	P2/P3	Acute Lymphoblastic Leukemia (ALL)	1,000	Jan 2026
NCT03017820	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	P1	B-Cell Non-Hodgkin Lymphoma	99	Apr 2017
NCT04744116	Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease	Early P1	Hematopoietic and Lymphoid Cell Neoplasm	24	Feb 2021
NCT05745714	HEM-iSMART CHEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	P1/P2	Acute Lymphoblastic Leukemia, in Relapse	26	Oct 2025
NCT07498205	APEX-MFComparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts	P4	Myelofibrosis	268	Aug 2026
NCT05088226	Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen	P2	Peripheral Blood Stem Cell Transplantation	50	Dec 2021
NCT06824103	Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease	P4	Graft vs. Host Disease	50	Sep 2025
NCT06327100	PMFOpen Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)	P1/P2	Primary Myelofibrosis	33	Aug 2024
NCT07311746	Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia	P1/P2	T-cell Prolymphocytic Leukemia	36	Jun 2026
NCT06615050	BMT CTN 2203A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)	P3	Graft-versus-host Disease (GVHD)	572	Apr 2025
NCT06991101	Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma	P2	Glioblastoma	190	Dec 2025
NCT07357727	MANIFEST-3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)	P3	Primary Myelofibrosis (PMF)	460	May 2026
NCT07340138	Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis	P1	Primary Myelofibrosis (PMF)	6	Apr 2026
NCT06128070	Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	P2	Acute Lymphoblastic Leukemia	40	Jul 2024
NCT07228624	Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes	P2	Myelodysplastic/Myeloproliferative Neoplasm	50	Feb 2026
NCT06616155	Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	P1/P2	Castration-Resistant Prostate Carcinoma	20	Jun 2026
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT07521046	Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)	P1	Myelofibrosis	15	May 2026
NCT07566897	A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors	P1	Renal Carcinoma Metastatic	96	May 2026
NCT07464951	CART123CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia	P1	Acute Myeloid Leukemia (AML)	30	May 2026
NCT04176198	TP-3654A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis	P1/P2	Myelofibrosis	240	Dec 2019
NCT04116502	MITHRIDATEMITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera	P3	Polycythemia Vera	586	Oct 2019
NCT05037760	A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis	P2	Myelofibrosis	135	Dec 2021
NCT06973668	A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease	P2	AML	80	Jul 2025
NCT07219576	PRISMRetifanlimab and Ruxolitinib In Solid Malignancies	P1/P2	Non Small Cell Lung Carcinoma	40	Jan 2026
NCT06160791	HLHRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)	P2	Hemophagocytic Lymphohistiocytoses	36	Oct 2024
NCT07252050	RUX-HAPLORuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease	P1/P2	Sickle Cell Disease	24	Jun 2026
NCT06756061	FRONTJAK-001Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity	P2	GVHD - Graft-Versus-Host Disease	88	Jan 2025
NCT06233110	Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD	P1	Chronic Graft Versus Host Disease	30	Oct 2025
NCT06477549	BeFluBu vs FluBuRux Conditioning in Haploidentical HCT	P2	Acute Lymphoblastic Leukemia	220	Jun 2024
NCT07032727	Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations	P2	Targeted Therapy	68	Sep 2025
NCT06209606	Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma	Early P1	Multiple Myeloma	30	Dec 2022
NCT07359859	A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant	P2	Hematologic Malignancies	40	Jan 2026
NCT07283822	Amping up With PemJAK	P2	Non-Hodgkin Lymphoma	53	Dec 2025
NCT07424222	RISERuxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)	P1	Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)	16	Jun 2026
NCT06345495	High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly	P2	Splenomegaly	30	Oct 2024
NCT07595939	Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo	P3	Vitiligo	20	Jun 2026
NCT07085039	Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease	P2	Castleman's Disease (CD)	14	Dec 2025
NCT06660355	Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy	P2	Chronic Graft-versus-host Disease (cGVHD)	120	Dec 2024
NCT06479135	POIESISStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	P3	Myelofibrosis	600	Jun 2024
NCT04856137	DLBLA Phase I/II Study of Diffuse Large B-cell Lymphoma	P1/P2	Refractory Diffuse Large B-cell Lymphoma	74	May 2021
NCT07101588	Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial	P4	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	200	Jan 2025
NCT03801434	Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	P2	BCR-JAK2 Fusion Protein Expression	10	Nov 2019
NCT07548983	Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation	P1	Acute Myeloid Leukemia	40	May 2026
NCT05980806	SENTRY-2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia	P2	Myelofibrosis	58	Apr 2024
NCT06034002	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	P1	Myeloproliferative Neoplasms	290	Dec 2023
NCT07617597	THRIVE-AAJPStudy to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata	P3	Alopecia Areata	78	Jun 2026
NCT07184853	RESCUERuxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD	N/A	Graft vs Host Disease	122	Sep 2025
NCT06536166	BIGTIMRuxolitinib Treatment in Inclusion Body Myositis	P2	Inclusion Body Myositis, Sporadic	80	May 2025
NCT05371964	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis	P1	Myelofibrosis	36	May 2022
NCT06079879	BATA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)	P3	Essential Thrombocythemia	340	Dec 2023
NCT06627335	An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis	—	Pregnancy Related	5,621	Mar 2023
NCT06859424	ACCELERATEA Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation	P2	AML (Acute Myelogenous Leukemia)	358	Jul 2025
NCT06364319	Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD	P4	cGVHD	118	Apr 2024
NCT07025538	Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation	P1	Hematopoietic and Lymphatic System Neoplasm	42	Jun 2026
NCT07588945	daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT	P3	Transplant-Related Disorder	438	Jun 2026
NCT07133308	Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata	P3	Alopecia Areata	355	Aug 2025
NCT05870475	PVPegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV	P2	Polycythemia Vera	94	Jun 2023
NCT06832618	TRuE-AD5A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis	P3	Atopic Dermatitis	240	Jun 2025
NCT06150157	CALRA Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms	P1	Neoplasms	220	Dec 2023
NCT06936566	MAGIC VMAGIC Ruxolitinib for aGVHD	P2	Acute Graft-versus-host Disease	98	May 2025
NCT05762640	R-HLHRuxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)	P2	Haemophagocytic Lymphohistiocytosis	20	Nov 2024
NCT07317700	A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis	P3	MF	105	Feb 2026
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	P1	Myeloproliferative Neoplasms	225	Sep 2023
NCT06462469	Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease	P4	Steroid-refractory Acute Graft Versus Host Disease	36	Jul 2024
NCT07366801	Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies	P2/P3	Acute Myeloid Leukemia, Relapsed	64	Sep 2025
NCT06773195	A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis	P1/P2	Myelofibrosis	37	Jan 2025
NCT07153666	A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo	—	Vitiligo	170	Dec 2025
NCT06857240	Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis	P2	Dermatomyositis	15	Jun 2025
NCT06199427	PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity	P2	Inborn Errors of Immunity	100	Nov 2023
NCT04061421	ABNL-MARROActive Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)	P1/P2	MDS/MPN	94	Nov 2021
NCT03874052	Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome	51	Aug 2019
NCT07509749	GVHDNovel Therapies for Severe Acute GVHD (Graft-versus-host Disease)	P2	GVHD, Acute	54	Jun 2025
NCT06804811	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo	P3	NonSegmental Vitiligo	250	Nov 2025
NCT05398809	APECEDEvaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata	P2	Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)	70	Jan 2023
NCT02974647	Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma	P2	Lymphoma	83	Nov 2016
NCT06008808	Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	P1	Graft Vs Host Disease	41	May 2024
NCT06397313	POTAMI-61RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis	P2	Myelofibrosis	230	Sep 2024
NCT03571321	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia	P1	Acute Lymphoblastic Leukemia	15	May 2019
NCT05010005	A Study of Ruxolitinib and Duvelisib in People With Lymphoma	P1	T-cell Lymphomas	70	Aug 2021
NCT03681561	Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma	P1/P2	Hodgkin Lymphoma	54	Sep 2018
NCT06959225	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)	P3	Hidradenitis Suppurativa	550	Jun 2025
NCT06958211	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)	P3	Hidradenitis Suppurativa	550	Jun 2025
NCT07249346	GVHDDose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation	P2	Leukemia	124	Jun 2026
NCT07340723	GVHDNovel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )	P2	GVHD,Acute	168	Jun 2025
NCT06225310	KPT-IST-391A Trial of Selinexor, Ruxolitinib and Methylprednisolone	P1	Multiple Myeloma in Relapse	30	Aug 2024
NCT05280509	Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib	P1/P2	Myelofibrosis	70	Jun 2022
NCT07278856	Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas	P1	Follicular Helper T-Cell Lymphoma	20	Dec 2025
NCT06548360	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo	P3	NonSegmental Vitiligo	180	Jan 2025
NCT03110822	RRMMA Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	P1	Multiple Myeloma	134	Feb 2017
NCT07356245	Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma	P2	T-cell Lymphoma	44	Feb 2026
NCT05714072	A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis	P1	Myelofibrosis Due to and Following Polycythemia Vera	18	Jan 2023
NCT06008275	Neratinib in Combination With Ruxolitinib in Patients With mTNBC	Early P1	Metastatic Triple-Negative Breast Carcinoma	20	Sep 2024
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	Alopecia Areata	150	Jul 2024
NCT05817955	Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN	P2	MDS/MPN	50	Nov 2022
NCT07238712	APTBCyOptimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor	P2	Acute Myeloid Leukemia (AML)	60	May 2025
NCT07049575	Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa	P1	Hidradenitis Suppurativa	24	Nov 2025
NCT04282187	Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms	P2	Acute Myeloid Leukemia	25	Mar 2020
NCT06607367	RESELECT2REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2	P1/P2	Poor Graft Function	20	Oct 2024
NCT06664970	A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor	P2	MDS	39	Nov 2024
NCT06075225	MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib	P2	GVHD	62	Oct 2023
NCT07588139	A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants	P1	Healthy Participants	24	May 2026
NCT05592015	Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia	P2	T-Cell Large Granular Lymphocyte Leukemia	30	May 2023
NCT06457425	A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis	P2	MF,PMF,PPV-MF,PET-MF	75	May 2024
NCT06291987	MPNIvosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	P1	Myeloproliferative Neoplasms	18	Sep 2024
NCT06261021	Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus	P2	Discoid Lupus Erythematosus	20	Apr 2024
NCT06719024	RCTTopical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus	P2/P3	Vitiligo	20	Nov 2024

Ruxolitinib clinical trials by indication

Myelofibrosis (43)

NCT	Acronym	Phase	Status	Title
NCT07498205	APEX-MF	P4	not yet recruiting	Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
NCT07521046	—	P1	not yet recruiting	Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
NCT04176198	TP-3654	P1/P2	recruiting	A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT05037760	—	P2	recruiting	A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT06479135	POIESIS	P3	recruiting	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT05980806	SENTRY-2	P2	recruiting	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05371964	—	P1	recruiting	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT04817007	—	P1/P2	active not recruiting	A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
+ 35 more, see All trials below.

Atopic Dermatitis (13)

NCT	Acronym	Phase	Status	Title
NCT06832618	TRuE-AD5	P3	recruiting	A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06238817	TRuE-AD4	P3	completed	A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT05696392	MORPHEUS	P4	terminated	The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT06673654	—	P1	completed	A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
NCT04921969	—	P3	completed	A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
NCT05127421	—	P2	completed	Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
NCT05034822	—	P1	completed	Study of Ruxolitinib Cream in Children With Atopic Dermatitis
NCT04839380	SCRATCH-AD	P2	completed	The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
+ 5 more, see All trials below.

Primary Myelofibrosis (12)

NCT	Acronym	Phase	Status	Title
NCT06327100	PMF	P1/P2	recruiting	Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
NCT04384692	—	P2	active not recruiting	Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
NCT02386800	—	P4	active not recruiting	CINC424A2X01B Rollover Protocol
NCT02251821	—	P2	completed	JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
NCT02917096	—	P1	completed	Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
NCT01981850	—	P2	completed	A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
NCT01969838	Simplify 1	P3	completed	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT02806375	—	P1/P2	completed	PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
+ 4 more, see All trials below.

Vitiligo (10)

NCT	Acronym	Phase	Status	Title
NCT07595939	—	P3	not yet recruiting	Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
NCT07153666	—	N/A	recruiting	A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
NCT06719024	RCT	P2/P3	recruiting	Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
NCT07368673	—	P4	completed	Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial
NCT05872477	PREVENT	P2	completed	Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
NCT05247489	—	P2	completed	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
NCT04896385	—	P2	completed	A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
NCT04530344	—	P3	completed	Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
+ 2 more, see All trials below.

Polycythemia Vera (9)

NCT	Acronym	Phase	Status	Title
NCT04116502	MITHRIDATE	P3	recruiting	MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT05870475	PV	P2	recruiting	Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
NCT05566535	QoL-PV-R	N/A	unknown	Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
NCT03669965	—	P2	unknown	KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
NCT05269771	—	N/A	no longer available	MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
NCT02038036	RESPONSE-2	P3	completed	Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
NCT01243944	INCB018424	P3	completed	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
NCT02292446	ETP	P3	completed	Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
+ 1 more, see All trials below.

COVID-19 (7)

NCT	Acronym	Phase	Status	Title
NCT04354714	—	P2	withdrawn	Ruxolitinib to Combat COVID-19
NCT04348071	—	P2/P3	withdrawn	Safety and Efficacy of Ruxolitinib for COVID-19
NCT04334044	—	P1/P2	completed	Treatment of SARS Caused by COVID-19 With Ruxolitinib
NCT04331665	—	N/A	terminated	Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
NCT04377620	RUXCOVID-DEVENT	P3	terminated	Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
NCT04414098	—	P2	unknown	Ruxolitinib in the Treatment of Covid-19
NCT04355793	—	N/A	no longer available	Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

Myelofibrosis (MF) (6)

NCT	Acronym	Phase	Status	Title
NCT07128381	MF	P1/P2	recruiting	Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
NCT04454658	—	P1	active not recruiting	Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
NCT04468984	TRANSFORM-2	P3	active not recruiting	Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04472598	TRANSFORM-1	P3	completed	Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
NCT03222609	REFINE	P2	completed	A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT04480086	—	P1	terminated	Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Acute Lymphoblastic Leukemia (6)

NCT	Acronym	Phase	Status	Title
NCT06128070	—	P2	recruiting	Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT06477549	—	P2	recruiting	BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
NCT03117751	—	P2/P3	active not recruiting	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03571321	—	P1	recruiting	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT02494882	—	P1	active not recruiting	Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02779283	—	P1	completed	Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Alopecia Areata (5)

NCT	Acronym	Phase	Status	Title
NCT07617597	THRIVE-AAJP	P3	not yet recruiting	Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
NCT07133308	—	P3	recruiting	Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT06573593	—	N/A	recruiting	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT02553330	AA	P2	terminated	A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT01950780	—	P2	completed	Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Hidradenitis Suppurativa (5)

NCT	Acronym	Phase	Status	Title
NCT06959225	—	P3	recruiting	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06958211	—	P3	recruiting	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT07049575	—	P1	recruiting	Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT05635838	—	P2	completed	Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
NCT04414514	—	P2	terminated	Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

Graft-versus-host Disease (GVHD) (5)

NCT	Acronym	Phase	Status	Title
NCT06615050	BMT CTN 2203	P3	recruiting	A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT05722912	—	N/A	approved for marketing	Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
NCT03112603	BAT	P3	completed	A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
NCT02953678	REACH-1	P2	completed	A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
NCT03147742	—	N/A	approved for marketing	An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

MPN (Myeloproliferative Neoplasms) (5)

NCT	Acronym	Phase	Status	Title
NCT02718300	—	P2	terminated	A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT03144687	—	P2	completed	A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
NCT03123588	RESET-272	P2	terminated	Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
NCT01348490	INCB018424	P2	completed	Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
NCT00952289	—	P3	completed	COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Leukemia (4)

NCT	Acronym	Phase	Status	Title
NCT07249346	GVHD	P2	recruiting	Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
NCT02723994	—	P2	completed	A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT01895842	MDS	P1	completed	Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01251965	—	P1/P2	terminated	Phase l/II Study of Ruxolitinib for Acute Leukemia

Acute Myeloid Leukemia (4)

NCT	Acronym	Phase	Status	Title
NCT07548983	—	P1	not yet recruiting	Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
NCT03286530	—	P2	active not recruiting	Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
NCT04282187	—	P2	recruiting	Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
NCT04055844	—	P2	completed	Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Psoriasis (4)

NCT	Acronym	Phase	Status	Title
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT00778700	—	P2	completed	A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
NCT00617994	—	P2	completed	Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
NCT00820950	—	P2	completed	A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Myeloproliferative Neoplasms (4)

NCT	Acronym	Phase	Status	Title
NCT06034002	—	P1	recruiting	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359	—	P1	recruiting	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT06291987	MPN	P1	recruiting	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
NCT02076191	—	P1/P2	completed	Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Essential Thrombocythemia (4)

NCT	Acronym	Phase	Status	Title
NCT04644211	—	P2	recruiting	Ruxolitinib in Thrombocythemia and Polycythemia Vera
NCT06079879	BAT	P3	recruiting	A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT03878199	—	P1/P2	terminated	Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
NCT02962388	—	P2/P3	terminated	The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Multiple Myeloma (4)

NCT	Acronym	Phase	Status	Title
NCT06209606	—	Early P1	recruiting	Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
NCT03110822	RRMM	P1	recruiting	A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03773107	MMRC-073 CARJAK	P1/P2	completed	LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
NCT00639002	JAK2	P2	completed	A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Pancreatic Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT02955940	—	P2	active not recruiting	An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
NCT02117479	—	P3	terminated	Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
NCT01423604	RECAP	P2	completed	Study of Ruxolitinib in Pancreatic Cancer Patients
NCT02119663	—	P3	terminated	A Study of Ruxolitinib in Pancreatic Cancer Patients

Transplant-Related Disorder (3)

NCT	Acronym	Phase	Status	Title
NCT07588945	—	P3	not yet recruiting	daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
NCT05599256	—	P2	unknown	Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
NCT05600855	—	P2	completed	Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Healthy Participants (3)

NCT	Acronym	Phase	Status	Title
NCT07588139	—	P1	recruiting	A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
NCT06555081	XR	P1	completed	A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
NCT06310304	XR	P1	completed	A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Primary Myelofibrosis (PMF) (3)

NCT	Acronym	Phase	Status	Title
NCT07357727	MANIFEST-3	P3	recruiting	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07340138	—	P1	recruiting	Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT04745637	—	N/A	available	Managed Access Programs for INC424, Ruxolitinib

Peripheral Blood Stem Cell Transplantation (3)

NCT	Acronym	Phase	Status	Title
NCT05088226	—	P2	recruiting	Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
NCT04582604	—	P1/P2	unknown	Ruxolitinib and Decitabine for High Risk Hematological Malignancies
NCT05075681	—	P1/P2	unknown	Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Hemophagocytic Lymphohistiocytosis (3)

NCT	Acronym	Phase	Status	Title
NCT04551131	—	P1/P2	active not recruiting	Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT03795909	—	P1/P2	unknown	Ruxolitinib Combined With Dexamethasone for HLH
NCT04120090	—	P3	unknown	Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

Anemia (3)

NCT	Acronym	Phase	Status	Title
NCT04455841	—	P1/P2	active not recruiting	INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
NCT01712308	—	P2	completed	Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
NCT01732445	—	P2	completed	Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Chronic Phase Chronic Myeloid Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT03610971	—	P2	active not recruiting	Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
NCT01702064	CML	P1	completed	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
NCT01914484	—	P1/P2	completed	Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Solid Tumors (3)

NCT	Acronym	Phase	Status	Title
NCT02587598	—	P1/P2	terminated	Study of INCB053914 in Subjects With Advanced Malignancies
NCT02711137	—	P1/P2	terminated	Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT01822756	—	P1	terminated	An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Acute Myeloid Leukemia (AML) (2)

NCT	Acronym	Phase	Status	Title
NCT07464951	CART123	P1	recruiting	CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
NCT07238712	APTBCy	P2	recruiting	Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

NonSegmental Vitiligo (2)

NCT	Acronym	Phase	Status	Title
NCT06804811	—	P3	recruiting	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06548360	—	P3	recruiting	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Chronic Graft Versus Host Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06233110	—	P1	recruiting	Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
NCT06695507	—	P1	terminated	Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Acute Lymphoblastic Leukemia, in Relapse (2)

NCT	Acronym	Phase	Status	Title
NCT05745714	HEM-iSMART C	P1/P2	recruiting	HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT03515200	—	P1	terminated	Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

AML (2)

NCT	Acronym	Phase	Status	Title
NCT06973668	—	P2	recruiting	A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
NCT02152956	VOYAGE	P1/P2	terminated	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Acute Graft-versus-host Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06936566	MAGIC V	P2	recruiting	MAGIC Ruxolitinib for aGVHD
NCT07576010	—	P1	active not recruiting	Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Atopic Dermatitis (AD) (2)

NCT	Acronym	Phase	Status	Title
NCT06923228	—	P2	completed	A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
NCT05456529	—	P3	completed	Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Hemophagocytic Lymphohistiocytoses (2)

NCT	Acronym	Phase	Status	Title
NCT06160791	HLH	P2	recruiting	Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
NCT05491304	—	P4	unknown	Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Graft Vs Host Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06008808	—	P1	recruiting	Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
NCT02997280	—	P2	completed	Ruxolitinib for Steroid-refractory GVHD

Discoid Lupus Erythematosus (2)

NCT	Acronym	Phase	Status	Title
NCT06261021	—	P2	recruiting	Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
NCT04908280	—	P2	completed	Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Prurigo Nodularis (2)

NCT	Acronym	Phase	Status	Title
NCT05764161	TRuE-PN2	P3	completed	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT06213831	—	P1	completed	A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Pregnancy Related (2)

NCT	Acronym	Phase	Status	Title
NCT06259669	OPERA-1	N/A	recruiting	Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
NCT06627335	—	N/A	recruiting	An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Hand Eczema (2)

NCT	Acronym	Phase	Status	Title
NCT05906628	—	P2	completed	Topical Ruxolitinib Evaluation in Chronic Hand Eczema
NCT05219864	TRuE-CHE1	P3	withdrawn	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

Acute-graft-versus-host Disease (2)

NCT	Acronym	Phase	Status	Title
NCT05123040	—	P1/P2	terminated	Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
NCT05121142	—	P1	completed	Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

MDS/MPN (2)

NCT	Acronym	Phase	Status	Title
NCT04061421	ABNL-MARRO	P1/P2	recruiting	Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT05817955	—	P2	recruiting	Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

Steroid Refractory GVHD (2)

NCT	Acronym	Phase	Status	Title
NCT05663827	—	P3	completed	Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
NCT05052385	—	N/A	completed	ECP Combination Study

Graft Versus Host Disease (2)

NCT	Acronym	Phase	Status	Title
NCT04838704	—	N/A	completed	Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation
NCT03395340	—	P2	terminated	Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Safety and Efficacy (2)

NCT	Acronym	Phase	Status	Title
NCT05021276	—	P4	unknown	Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
NCT04446806	—	P4	unknown	Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

Covid-19 (2)

NCT	Acronym	Phase	Status	Title
NCT04338958	RuxCoFlam	P2	completed	Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation
NCT04366232	JAKINCOV	P2	terminated	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

Severe Acute Respiratory Syndrome Coronavirus 2 (2)

NCT	Acronym	Phase	Status	Title
NCT04477993	RUXO-COVID	P2/P3	terminated	Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
NCT04361903	RESPIRE	N/A	unknown	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

Non-segmental Vitiligo (2)

NCT	Acronym	Phase	Status	Title
NCT04052425	—	P3	completed	Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
NCT04057573	—	P3	completed	Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

aGVHD (2)

NCT	Acronym	Phase	Status	Title
NCT04061876	—	P2	completed	First Line Therapy for High Risk Acute GVHD
NCT04397367	—	P1/P2	completed	Low Dose Ruxolitinib in Combination With Methylprednisolone

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT03874052	—	P1	recruiting	Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01620216	—	P2	terminated	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Head and Neck Squamous Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03153982	—	P2	terminated	Ruxolitinib in Operable Head and Neck Cancer
NCT02593929	—	Early P1	withdrawn	Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Prostate Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03274778	—	N/A	withdrawn	Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
NCT00638378	INCB018424	P2	terminated	Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Hodgkin's Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT02613598	—	P1	completed	Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
NCT01877005	HIJAK	P2	completed	A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Myeloproliferative Diseases (2)

NCT	Acronym	Phase	Status	Title
NCT01375140	—	P2	completed	Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
NCT02267278	MF	P2	completed	Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT02131584	—	P2	active not recruiting	Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
NCT02015208	—	P1/P2	completed	Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02120417	—	P2	terminated	A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
NCT01562873	—	P2	terminated	Ruxolitinib in Patients With Breast Cancer

Primary Myelofibrosis (MF) (2)

NCT	Acronym	Phase	Status	Title
NCT01392443	MF	P2	completed	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
NCT02087059	PM	P3	completed	A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Castration-Resistant Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06616155	—	P1/P2	recruiting	Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Hematopoietic and Lymphatic System Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT07025538	—	P1	recruiting	Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

T-cell Prolymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT07311746	—	P1/P2	not yet recruiting	Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) (1)

NCT	Acronym	Phase	Status	Title
NCT07424222	RISE	P1	not yet recruiting	Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

Sickle Cell Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07252050	RUX-HAPLO	P1/P2	recruiting	Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Renal Carcinoma Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT07566897	—	P1	not yet recruiting	A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Follicular Helper T-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07278856	—	P1	recruiting	Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

MF (1)

NCT	Acronym	Phase	Status	Title
NCT07317700	—	P3	recruiting	A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07356245	—	P2	recruiting	Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Myelodysplastic/Myeloproliferative Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT07228624	—	P2	recruiting	Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Hematologic Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT07359859	—	P2	recruiting	A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Acute Lymphoblastic Leukemia (ALL) (1)

NCT	Acronym	Phase	Status	Title
NCT07297914	FORUM2	P2/P3	not yet recruiting	Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

Non Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07219576	PRISM	P1/P2	recruiting	Retifanlimab and Ruxolitinib In Solid Malignancies

Castleman's Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT07085039	—	P2	recruiting	Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07283822	—	P2	recruiting	Amping up With PemJAK

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT06991101	—	P2	recruiting	Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Graft vs Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07184853	RESCUE	N/A	recruiting	Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Aplastic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT06752694	—	P2	active not recruiting	Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Targeted Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT07032727	—	P2	recruiting	Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Graft vs. Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06824103	—	P4	recruiting	Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Acute Myeloid Leukemia, Relapsed (1)

NCT	Acronym	Phase	Status	Title
NCT07366801	—	P2/P3	recruiting	Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly (1)

NCT	Acronym	Phase	Status	Title
NCT06909136	—	P1/P2	active not recruiting	A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis

AML (Acute Myelogenous Leukemia) (1)

NCT	Acronym	Phase	Status	Title
NCT06859424	ACCELERATE	P2	recruiting	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

GVHD, Acute (1)

NCT	Acronym	Phase	Status	Title
NCT07509749	GVHD	P2	recruiting	Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

GVHD,Acute (1)

NCT	Acronym	Phase	Status	Title
NCT07340723	GVHD	P2	recruiting	Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Dermatomyositis (1)

NCT	Acronym	Phase	Status	Title
NCT06857240	—	P2	recruiting	Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

Inclusion Body Myositis, Sporadic (1)

NCT	Acronym	Phase	Status	Title
NCT06536166	BIGTIM	P2	recruiting	Ruxolitinib Treatment in Inclusion Body Myositis

Relapsed AML (1)

NCT	Acronym	Phase	Status	Title
NCT06768476	AML	P1	active not recruiting	CART123 + Ruxolitinib in Relapsed/Refractory AML

GVHD - Graft-Versus-Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06756061	FRONTJAK-001	P2	recruiting	Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (1)

NCT	Acronym	Phase	Status	Title
NCT07101588	—	P4	recruiting	Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Chronic Graft-versus-host Disease (cGVHD) (1)

NCT	Acronym	Phase	Status	Title
NCT06660355	—	P2	recruiting	Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Haemophagocytic Lymphohistiocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT05762640	R-HLH	P2	recruiting	Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

MDS (1)

NCT	Acronym	Phase	Status	Title
NCT06664970	—	P2	enrolling by invitation	A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Poor Graft Function (1)

NCT	Acronym	Phase	Status	Title
NCT06607367	RESELECT2	P1/P2	not yet recruiting	REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

Chronic Graft-versus-host-disease (1)

NCT	Acronym	Phase	Status	Title
NCT06388564	—	P2	active not recruiting	A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Exanthema (1)

NCT	Acronym	Phase	Status	Title
NCT06399029	TRUX-LST	P2	active not recruiting	Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Splenomegaly (1)

NCT	Acronym	Phase	Status	Title
NCT06345495	—	P2	recruiting	High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Metastatic Triple-Negative Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06008275	—	Early P1	recruiting	Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Multiple Myeloma in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT06225310	KPT-IST-391	P1	recruiting	A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Steroid-refractory Acute Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06462469	—	P4	recruiting	Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Neuromyelitis Optica Spectrum Disorder Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT05909943	—	P1/P2	withdrawn	Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

MF,PMF,PPV-MF,PET-MF (1)

NCT	Acronym	Phase	Status	Title
NCT06457425	—	P2	recruiting	A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

cGVHD (1)

NCT	Acronym	Phase	Status	Title
NCT06364319	—	P4	not yet recruiting	Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Severe Aplastic Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT05998408	—	P1/P2	active not recruiting	JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Hemophagocytic Syndromes (1)

NCT	Acronym	Phase	Status	Title
NCT06244862	JAKAHDI	P2	unknown	JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06150157	CALR	P1	recruiting	A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Inborn Errors of Immunity (1)

NCT	Acronym	Phase	Status	Title
NCT06199427	—	P2	recruiting	PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT06075225	—	P2	not yet recruiting	MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Kohlmeier Degos Disease With Neurologic Involvement (1)

NCT	Acronym	Phase	Status	Title
NCT05998395	—	P1/P2	completed	JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Graft-versus-host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05622318	GVHD	P2	active not recruiting	De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA (1)

NCT	Acronym	Phase	Status	Title
NCT05914714	—	P2	unknown	Ruxolitinib as GVHD Prophylaxis in AA Patients

T-Cell Large Granular Lymphocyte Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05592015	—	P2	recruiting	Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Severe Checkpoint Inhibitor Pneumonitis (1)

NCT	Acronym	Phase	Status	Title
NCT05899725	—	N/A	unknown	The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Nonsegmental Vitiligo With Genital Involvement (1)

NCT	Acronym	Phase	Status	Title
NCT05750823	—	P2	completed	A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Hematologic Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT05579769	—	P2	terminated	Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Prurigo (1)

NCT	Acronym	Phase	Status	Title
NCT05755438	TRuE-PN1	P3	completed	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Chronic Hand Eczema (CHE) (1)

NCT	Acronym	Phase	Status	Title
NCT05233410	TRuE-CHE2	P3	withdrawn	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Myelofibrosis Due to and Following Polycythemia Vera (1)

NCT	Acronym	Phase	Status	Title
NCT05714072	—	P1	recruiting	A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Pancreatic Ductal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05440942	—	P1	completed	Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced) (1)

NCT	Acronym	Phase	Status	Title
NCT05398809	APECED	P2	recruiting	Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Cutaneous Lichen Planus (1)

NCT	Acronym	Phase	Status	Title
NCT05593432	—	P2	completed	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Lichen Sclerosus (1)

NCT	Acronym	Phase	Status	Title
NCT05593445	—	P2	completed	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Seborrheic Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05787860	—	P2	completed	Ruxolitinib in Seborrheic Dermatitis

Chronic Hand Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05293717	—	P1/P2	completed	Topical Ruxolitinib in Chronic Hand Dermatitis

Steroid-Refractory Acute Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04934670	2002	P3	terminated	A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Macrophage Activation Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05137496	—	P3	unknown	Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

Bronchiolitis Obliterans Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05413356	—	P2	unknown	Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Advanced Cutaneous Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04807777	—	P2	terminated	Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Stage IV Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04906746	—	Early P1	active not recruiting	Ruxolitinib for Cancer Cachexia

Hematopoietic Stem Cell Transplant (HSCT) (1)

NCT	Acronym	Phase	Status	Title
NCT04908735	HSCT	P2	terminated	Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

Allogeneic Hematopoietic Cell Transplantation (HCT) (1)

NCT	Acronym	Phase	Status	Title
NCT05088356	—	P1	active not recruiting	Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

T-cell Lymphomas (1)

NCT	Acronym	Phase	Status	Title
NCT05010005	—	P1	recruiting	A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Hemophagocytic Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04999878	RUE-DDGP	P4	unknown	A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

Refractory Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04856137	DLBL	P1/P2	not yet recruiting	A Phase I/II Study of Diffuse Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04744116	—	Early P1	recruiting	Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Accelerated/Blast-phase Myeloproliferative Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04281498	—	P2	completed	Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Graft-versus-host-disease (1)

NCT	Acronym	Phase	Status	Title
NCT04669210	PTCyRuxo	P2	completed	PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT

Coronavirus (1)

NCT	Acronym	Phase	Status	Title
NCT04581954	MATIS	P1/P2	completed	Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Necrobiosis Lipoidica (1)

NCT	Acronym	Phase	Status	Title
NCT04492618	—	P2	completed	Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Malaria (1)

NCT	Acronym	Phase	Status	Title
NCT04456634	—	P1	completed	Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

Covid19 (1)

NCT	Acronym	Phase	Status	Title
NCT04424056	INFLAMMACOV	P3	unknown	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease

B-Cell Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT04509700	INCB050465	P2	active not recruiting	Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

ARDS, Human (1)

NCT	Acronym	Phase	Status	Title
NCT04359290	RuXoCoil	P2	completed	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

COVID 19 (1)

NCT	Acronym	Phase	Status	Title
NCT04403243	COLORIT	P2	completed	COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

Cytokine Storm (Covid-19) (1)

NCT	Acronym	Phase	Status	Title
NCT04362137	RUXCOVID	P3	completed	Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

Cytokine Release Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04374149	—	P2	completed	Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Coronavirus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04348695	Ruxo-Sim-20	P2	completed	Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03878524	SMMART	P1	terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Solid Tumor, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT04328844	IOA-244	P1	active not recruiting	A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04016116	—	P2	withdrawn	Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

BCR-JAK2 Fusion Protein Expression (1)

NCT	Acronym	Phase	Status	Title
NCT03801434	—	P2	recruiting	Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Myeloproliferative Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04041050	—	P1	active not recruiting	A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Intestinal GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT04269850	JAK-FMT	P1/P2	terminated	Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Chronic Myelomonocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03722407	CMML	P2	active not recruiting	Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Non-sclerotic Cutaneous Chronic Graft-versus-host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03954236	—	P2	active not recruiting	Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Other Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03674047	BOS	P2	active not recruiting	Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Acute Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03491215	—	P1/P2	completed	Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute T Cell Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03613428	—	P1/P2	unknown	Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Acute GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT03701698	—	P2	terminated	Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03654768	—	P2	active not recruiting	Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03681561	—	P1/P2	recruiting	Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Graft-versus-host-disease (GVHD) (1)

NCT	Acronym	Phase	Status	Title
NCT03616184	—	P2	completed	Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04303403	—	P1	unknown	Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03514069	—	P1	completed	Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT03558607	—	P1/P2	unknown	The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Ductal Carcinoma In Situ (1)

NCT	Acronym	Phase	Status	Title
NCT02928978	TBCRC042	P2	completed	Ruxolitinib for Premalignant Breast Disease

Myelofibroses (1)

NCT	Acronym	Phase	Status	Title
NCT03386214	—	P1	terminated	Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Leukemia, Chronic Myeloid (1)

NCT	Acronym	Phase	Status	Title
NCT02973711	—	P1/P2	withdrawn	A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Inflammatory Breast Cancer (IBC) (1)

NCT	Acronym	Phase	Status	Title
NCT02876302	INCB018424	P2	active not recruiting	Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Metastatic Malignant Neoplasm in the Bone (1)

NCT	Acronym	Phase	Status	Title
NCT03012230	—	P1	completed	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Metastatic Endometrial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03120624	—	P1	active not recruiting	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03017820	—	P1	recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell (1)

NCT	Acronym	Phase	Status	Title
NCT02912754	—	P1/P2	unknown	Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Corticosteroid Refractory Acute Graft vs Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02913261	REACH2	P3	completed	Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03041636	—	P2	completed	Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Bone Marrow Fibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT03333187	—	P2	active not recruiting	Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02974647	—	P2	recruiting	Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Fallopian Tube Clear Cell Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02713386	—	P1/P2	completed	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

HIV Infections (1)

NCT	Acronym	Phase	Status	Title
NCT02475655	—	P2	completed	Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

Hemophagocytic Syndrome (HPS) (1)

NCT	Acronym	Phase	Status	Title
NCT02400463	—	P2	completed	A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Myelofibrosis With High Molecular Risk Mutations (1)

NCT	Acronym	Phase	Status	Title
NCT02598297	ReTHINK	P3	terminated	Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Relapsed Pediatric Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT02638428	—	P2	unknown	Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Acute Myeloid Leukemia in Remission (1)

NCT	Acronym	Phase	Status	Title
NCT02528877	—	P1	withdrawn	Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Polycythemia Vera (PV) (1)

NCT	Acronym	Phase	Status	Title
NCT02577926	Ruxo-BEAT	P2	active not recruiting	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Recurrent Classical Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02164500	JeRiCHO	P2	completed	JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Recurrent B Acute Lymphoblastic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02420717	—	P2	terminated	Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02145637	NSCLC	P1	completed	Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Chronic Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02253277	CoRNea	P1	completed	Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

Blasts More Than 20 Percent of Bone Marrow Nucleated Cells (1)

NCT	Acronym	Phase	Status	Title
NCT02257138	—	P1/P2	completed	Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (1)

NCT	Acronym	Phase	Status	Title
NCT02092324	—	P2	completed	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02155465	—	P1/P2	completed	Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02066532	—	P1/P2	completed	Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Thalassemia Major (1)

NCT	Acronym	Phase	Status	Title
NCT02049450	—	P2	completed	Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

Cancer Cachexia (1)

NCT	Acronym	Phase	Status	Title
NCT02072057	—	P2	terminated	Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

CRC (Colorectal Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT02119676	—	P2	terminated	Study of Ruxolitinib in Colorectal Cancer Patients

Recurrent Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02041429	—	P1/P2	completed	Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NSCLC (Non-small Cell Lung Carcinoma) (1)

NCT	Acronym	Phase	Status	Title
NCT02119650	—	P2	terminated	Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Relapsed or Refractory Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01965119	JAK2	P2	completed	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT01751425	—	P1	terminated	Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (1)

NCT	Acronym	Phase	Status	Title
NCT01787487	—	P2	completed	Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Myelomonocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT01776723	—	P1/P2	completed	A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

T Cell Leukemia, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT01712659	—	P1/P2	terminated	Ruxolitinib for Adult T-Cell Leukemia

Estrogen-receptor Positive Invasive Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01594216	—	P2	completed	Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Idiopathic Myelofibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT01433445	—	P1	completed	Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Recurrent Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01431209	—	P2	completed	Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

Chronic Myeloproliferative Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT01164163	—	P1	completed	INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Myeloproliferative Neoplasm (MPN) (1)

NCT	Acronym	Phase	Status	Title
NCT00726232	—	P2	terminated	Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Eosinophilic Myeloid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT00044304	—	P2	active not recruiting	Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Erythrocytosis, Familial, 2 (1)

NCT	Acronym	Phase	Status	Title
NCT01730755	—	N/A	no longer available	Ruxolitinib for Chuvash Polycythemia

Severe/Very Severe COVID-19 Illness (1)

NCT	Acronym	Phase	Status	Title
NCT04337359	MAP	N/A	no longer available	Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Ruxolitinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
APEX-MF	NCT07498205	P4	not yet recruiting	Myelofibrosis	268	—
MORPHEUS	NCT05696392	P4	terminated	Atopic Dermatitis	47	—
RUE-DDGP	NCT04999878	P4	unknown	Hemophagocytic Syndrome	30	—
BMT CTN 2203	NCT06615050	P3	recruiting	Graft-versus-host Disease (GVHD)	572	—
MANIFEST-3	NCT07357727	P3	recruiting	Primary Myelofibrosis (PMF)	460	—
MITHRIDATE	NCT04116502	P3	recruiting	Polycythemia Vera	586	—
POIESIS	NCT06479135	P3	recruiting	Myelofibrosis	600	—
THRIVE-AAJP	NCT07617597	P3	not yet recruiting	Alopecia Areata	78	—
BAT	NCT06079879	P3	recruiting	Essential Thrombocythemia	340	—
TRuE-AD5	NCT06832618	P3	recruiting	Atopic Dermatitis	240	—
SENTRY	NCT04562389	P3	active not recruiting	Myelofibrosis	353	PMID 39911057
MANIFEST-2	NCT04603495	P3	active not recruiting	Myelofibrosis	430	PMID 40065169
TRANSFORM-2	NCT04468984	P3	active not recruiting	Myelofibrosis (MF)	330	—
TRuE-PN2	NCT05764161	P3	completed	Prurigo Nodularis	190	—
TRuE-AD4	NCT06238817	P3	completed	Atopic Dermatitis	241	—
TRuE-PN1	NCT05755438	P3	completed	Prurigo	204	—
TRANSFORM-1	NCT04472598	P3	completed	Myelofibrosis (MF)	252	—
LIMBER-313	NCT04551066	P3	terminated	Myelofibrosis	252	—
TRuE-CHE1	NCT05219864	P3	withdrawn	Hand Eczema	0	—
TRuE-CHE2	NCT05233410	P3	withdrawn	Chronic Hand Eczema (CHE)	0	—
LIMBER-304	NCT04551053	P3	terminated	Myelofibrosis	177	—
2002	NCT04934670	P3	terminated	Steroid-Refractory Acute Graft Versus Host Disease	12	PMID 37749187
BAT	NCT03112603	P3	completed	Graft-versus-host Disease (GVHD)	330	PMID 40561385
INFLAMMACOV	NCT04424056	P3	unknown	Covid19	216	—
REACH2	NCT02913261	P3	completed	Corticosteroid Refractory Acute Graft vs Host Disease	310	PMID 32320566
RUXCOVID-DEVENT	NCT04377620	P3	terminated	COVID-19	211	PMID 36226977
RUXCOVID	NCT04362137	P3	completed	Cytokine Storm (Covid-19)	432	PMID 35368384
RESPONSE-2	NCT02038036	P3	completed	Polycythemia Vera	149	PMID 35597252
Simplify 1	NCT01969838	P3	completed	Primary Myelofibrosis	432	PMID 37042865
INCB018424	NCT01243944	P3	completed	Polycythemia Vera	222	PMID 27102499
ETP	NCT02292446	P3	completed	Polycythemia Vera	161	—
ReTHINK	NCT02598297	P3	terminated	Myelofibrosis With High Molecular Risk Mutations	49	—
PM	NCT02087059	P3	completed	Primary Myelofibrosis (MF)	51	—
JAK	NCT00934544	P3	completed	Myelofibrosis	219	PMID 24056820
HLH	NCT06160791	P2	recruiting	Hemophagocytic Lymphohistiocytoses	36	—
FRONTJAK-001	NCT06756061	P2	recruiting	GVHD - Graft-Versus-Host Disease	88	PMID 34260836
Ruxo-BEAT	NCT02577926	P2	active not recruiting	Polycythemia Vera (PV)	207	PMID 36564535
SENTRY-2	NCT05980806	P2	recruiting	Myelofibrosis	58	—
BIGTIM	NCT06536166	P2	recruiting	Inclusion Body Myositis, Sporadic	80	—
ACCELERATE	NCT06859424	P2	recruiting	AML (Acute Myelogenous Leukemia)	358	—
PV	NCT05870475	P2	recruiting	Polycythemia Vera	94	—
MAGIC V	NCT06936566	P2	recruiting	Acute Graft-versus-host Disease	98	—
R-HLH	NCT05762640	P2	recruiting	Haemophagocytic Lymphohistiocytosis	20	—
GVHD	NCT07509749	P2	recruiting	GVHD, Acute	54	PMID 38804281
APECED	NCT05398809	P2	recruiting	Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)	70	—
POTAMI-61	NCT06397313	P2	recruiting	Myelofibrosis	230	—
INCB050465	NCT04509700	P2	active not recruiting	B-Cell Malignancies	112	—
GVHD	NCT07249346	P2	recruiting	Leukemia	124	—
GVHD	NCT07340723	P2	recruiting	GVHD,Acute	168	PMID 30453910
APTBCy	NCT07238712	P2	recruiting	Acute Myeloid Leukemia (AML)	60	PMID 40372957
GVHD	NCT05622318	P2	active not recruiting	Graft-versus-host Disease	56	—
CMML	NCT03722407	P2	active not recruiting	Chronic Myelomonocytic Leukemia	29	—
TRUX-LST	NCT06399029	P2	active not recruiting	Exanthema	22	—
INCB018424	NCT02876302	P2	active not recruiting	Inflammatory Breast Cancer (IBC)	23	PMID 38297352
JAKAHDI	NCT06244862	P2	unknown	Hemophagocytic Syndromes	42	—
BOS	NCT03674047	P2	active not recruiting	Other Cancer	50	PMID 39365992
HSCT	NCT04908735	P2	terminated	Hematopoietic Stem Cell Transplant (HSCT)	7	—
PTCyRuxo	NCT04669210	P2	completed	Graft-versus-host-disease	128	PMID 42066960
REFINE	NCT03222609	P2	completed	Myelofibrosis (MF)	191	PMID 40454409
PREVENT	NCT05872477	P2	completed	Vitiligo	20	—
TBCRC042	NCT02928978	P2	completed	Ductal Carcinoma In Situ	84	—
SCRATCH-AD	NCT04839380	P2	completed	Atopic Dermatitis	49	—
RuXoCoil	NCT04359290	P2	completed	ARDS, Human	15	PMID 34385593
RuxCoFlam	NCT04338958	P2	completed	Covid-19	193	PMID 32518419
Ruxo-Sim-20	NCT04348695	P2	completed	Coronavirus Infection	94	PMID 33240091
JAKINCOV	NCT04366232	P2	terminated	Covid-19	2	PMID 28895072
COLORIT	NCT04403243	P2	completed	COVID 19	70	PMID 34658014
RESET-272	NCT03123588	P2	terminated	MPN (Myeloproliferative Neoplasms)	12	—
REACH-1	NCT02953678	P2	completed	Graft-versus-host Disease (GVHD)	71	PMID 32160294
JeRiCHO	NCT02164500	P2	completed	Recurrent Classical Hodgkin Lymphoma	12	—
REALISE	NCT02966353	P2	completed	Primary Myelofibrosis	51	—
INCB018424	NCT01348490	P2	completed	MPN (Myeloproliferative Neoplasms)	66	PMID 34911667
JAK2	NCT01965119	P2	completed	Relapsed or Refractory Hodgkin Lymphoma	20	PMID 31707975
HIJAK	NCT01877005	P2	completed	Hodgkin's Lymphoma	33	PMID 29351986
MF	NCT02267278	P2	completed	Myeloproliferative Diseases	25	—
MF	NCT01392443	P2	completed	Primary Myelofibrosis (MF)	120	PMID 27801315
AA	NCT02553330	P2	terminated	Alopecia Areata	90	PMID 28619556
RECAP	NCT01423604	P2	completed	Pancreatic Cancer	136	PMID 26351344
INCB018424	NCT01340651	P2	completed	Myelofibrosis	41	—
JAK2	NCT00639002	P2	completed	Multiple Myeloma	13	—
INCB018424	NCT00638378	P2	terminated	Prostate Cancer	22	—

Terminated and withdrawn Ruxolitinib trials (65)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05909943withdrawnEfficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
NCT05123040terminatedRuxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
NCT04908735terminatedRuxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
NCT06695507terminatedUpfront Ruxolitinib for Chronic Graft-vs-host Disease
NCT06619522withdrawnA Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
NCT03878199terminatedTesting the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
NCT05696392terminatedThe Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT04269850terminatedFecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
NCT04551066terminatedTo Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT05219864withdrawnTopical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
NCT05233410withdrawnTopical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
NCT03701698terminatedRuxolitinib and Steroid As First Line Therapy for Acute GVHD
NCT04097821terminatedPlatform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04551053terminatedTo Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT05579769terminatedPediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
NCT04414514terminatedTopical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT03153982terminatedRuxolitinib in Operable Head and Neck Cancer
NCT04807777terminatedStudy of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
NCT04480086terminatedSafety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
NCT04354727withdrawnA Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
NCT04934670terminatedA Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
NCT04543279terminatedFostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
NCT02152956terminatedFlotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
NCT02718300terminatedA Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT01712659terminatedRuxolitinib for Adult T-Cell Leukemia
NCT04354714withdrawnRuxolitinib to Combat COVID-19
NCT04016116withdrawnDual PD-1 and JAK2 Inhibition in Hematological Malignancies
NCT04348071withdrawnSafety and Efficacy of Ruxolitinib for COVID-19
NCT03386214terminatedPevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
NCT02973711withdrawnA Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
NCT02962388terminatedThe Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
NCT04477993terminatedRuxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
NCT04331665terminatedStudy of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
NCT04377620terminatedAssessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
NCT02420717terminatedRuxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT04366232terminatedEfficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation
NCT02587598terminatedStudy of INCB053914 in Subjects With Advanced Malignancies
NCT03123588terminatedPhase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
NCT03515200terminatedTreatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03274778withdrawnEffect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
NCT03373877terminatedEvaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT01751425terminatedRuxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
NCT02711137terminatedOpen-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT03395340terminatedTopical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
NCT02072057terminatedStudy of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
NCT00726232terminatedStudy to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
NCT02436135terminatedStudy to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
NCT01790295terminatedRuxolitinib Prior to Transplant in Patients With Myelofibrosis
NCT02598297terminatedPhase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
NCT02553330terminatedA Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
NCT01620216terminatedTargeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT02593929withdrawnPharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
NCT02120417terminatedA Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
NCT02117479terminatedStudy of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
NCT02119676terminatedStudy of Ruxolitinib in Colorectal Cancer Patients
NCT02119663terminatedA Study of Ruxolitinib in Pancreatic Cancer Patients
NCT02469974withdrawnRuxolitinib in Combination With Autotransplant
NCT01822756terminatedAn Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
NCT01562873terminatedRuxolitinib in Patients With Breast Cancer
NCT02119650terminatedRuxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
NCT02528877withdrawnRuxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
NCT02091752terminatedA Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
NCT01251965terminatedPhase l/II Study of Ruxolitinib for Acute Leukemia
NCT00638378terminatedStudy of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

All Ruxolitinib trials (388)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06768476	AML	CART123 + Ruxolitinib in Relapsed/Refractory AML	P1	active not recruiting	12	University of Pennsylvania	Feb 2025
NCT04644211		Ruxolitinib in Thrombocythemia and Polycythemia Vera	P2	recruiting	60	Massachusetts General Hospital	Mar 2022
NCT06259669	OPERA-1	Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population	—	recruiting	958	Incyte Corporation	Sep 2023
NCT07128381	MF	Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)	P1/P2	recruiting	66	M.D. Anderson Cancer Center	Jan 2026
NCT07297914	FORUM2	Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL	P2/P3	not yet recruiting	1,000	Bambino Gesù Hospital and Research Institute	Jan 2026
NCT05998408		JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure	P1/P2	active not recruiting	13	National Heart, Lung, and Blood Institute (NHLBI)	Feb 2024
NCT03017820		A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	P1	recruiting	99	Mayo Clinic	Apr 2017
NCT04744116		Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease	Early P1	recruiting	24	M.D. Anderson Cancer Center	Feb 2021
NCT05745714	HEM-iSMART C	HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies	P1/P2	recruiting	26	Princess Maxima Center for Pediatric Oncology	Oct 2025
NCT07498205	APEX-MF	Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts	P4	not yet recruiting	268	SWOG Cancer Research Network	Aug 2026
NCT05088226		Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen	P2	recruiting	50	Chinese PLA General Hospital	Dec 2021
NCT06824103		Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease	P4	recruiting	50	Novartis Pharmaceuticals	Sep 2025
NCT06327100	PMF	Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)	P1/P2	recruiting	33	M.D. Anderson Cancer Center	Aug 2024
NCT07311746		Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia	P1/P2	not yet recruiting	36	M.D. Anderson Cancer Center	Jun 2026
NCT06615050	BMT CTN 2203	A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)	P3	recruiting	572	Incyte Corporation	Apr 2025
NCT06991101		Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma	P2	recruiting	190	Baptist Health South Florida	Dec 2025
NCT07357727	MANIFEST-3	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)	P3	recruiting	460	Novartis Pharmaceuticals	May 2026
NCT07340138		Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis	P1	recruiting	6	Novartis Pharmaceuticals	Apr 2026
NCT06128070		Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	P2	recruiting	40	City of Hope Medical Center	Jul 2024
NCT07228624		Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes	P2	recruiting	50	Fred Hutchinson Cancer Center	Feb 2026
NCT06616155		Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	P1/P2	recruiting	20	University of Michigan Rogel Cancer Center	Jun 2026
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT07521046		Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)	P1	not yet recruiting	15	University of Utah	May 2026
NCT07566897		A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors	P1	not yet recruiting	96	Philogen S.p.A.	May 2026
NCT07464951	CART123	CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia	P1	recruiting	30	Stephan Grupp MD PhD	May 2026
NCT04176198	TP-3654	A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis	P1/P2	recruiting	240	Sumitomo Pharma America, Inc.	Dec 2019
NCT04384692		Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis	P2	active not recruiting	53	Fred Hutchinson Cancer Center	Dec 2020
NCT04116502	MITHRIDATE	MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera	P3	recruiting	586	University of Birmingham	Oct 2019
NCT05037760		A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis	P2	recruiting	135	Takeda	Dec 2021
NCT06973668		A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease	P2	recruiting	80	M.D. Anderson Cancer Center	Jul 2025
NCT07219576	PRISM	Retifanlimab and Ruxolitinib In Solid Malignancies	P1/P2	recruiting	40	University of California, San Diego	Jan 2026
NCT06388564		A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease	P2	active not recruiting	130	Incyte Corporation	Oct 2024
NCT06160791	HLH	Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)	P2	recruiting	36	Jerry Lee, MD, MSc, MPhil	Oct 2024
NCT07252050	RUX-HAPLO	Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease	P1/P2	recruiting	24	Arkansas Children's Hospital Research Institute	Jun 2026
NCT06756061	FRONTJAK-001	Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity	P2	recruiting	88	Byung-Sik Cho	Jan 2025
NCT06233110		Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD	P1	recruiting	30	Stefanie Sarantopoulos, MD, PhD.	Oct 2025
NCT06477549		BeFluBu vs FluBuRux Conditioning in Haploidentical HCT	P2	recruiting	220	St. Petersburg State Pavlov Medical University	Jun 2024
NCT07032727		Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations	P2	recruiting	68	M.D. Anderson Cancer Center	Sep 2025
NCT06209606		Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma	Early P1	recruiting	30	Oncotherapeutics	Dec 2022
NCT07359859		A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant	P2	recruiting	40	Memorial Sloan Kettering Cancer Center	Jan 2026
NCT07283822		Amping up With PemJAK	P2	recruiting	53	Seda S. Tolu	Dec 2025
NCT07424222	RISE	Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)	P1	not yet recruiting	16	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Jun 2026
NCT06345495		High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly	P2	recruiting	30	M.D. Anderson Cancer Center	Oct 2024
NCT07595939		Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo	P3	not yet recruiting	20	The Children's Hospital of Zhejiang University School of Medicine	Jun 2026
NCT07085039		Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease	P2	recruiting	14	University of Pennsylvania	Dec 2025
NCT06660355		Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy	P2	recruiting	120	H. Lee Moffitt Cancer Center and Research Institute	Dec 2024
NCT06479135	POIESIS	Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib	P3	recruiting	600	Kartos Therapeutics, Inc.	Jun 2024
NCT04856137	DLBL	A Phase I/II Study of Diffuse Large B-cell Lymphoma	P1/P2	not yet recruiting	74	National Health Research Institutes, Taiwan	May 2021
NCT02577926	Ruxo-BEAT	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	P2	active not recruiting	207	RWTH Aachen University	Oct 2015
NCT07101588		Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial	P4	recruiting	200	Chinese PLA General Hospital	Jan 2025
NCT03801434		Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	P2	recruiting	10	William Shomali	Nov 2019
NCT07548983		Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation	P1	not yet recruiting	40	OHSU Knight Cancer Institute	May 2026
NCT05980806	SENTRY-2	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia	P2	recruiting	58	Karyopharm Therapeutics Inc	Apr 2024
NCT06034002		A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	P1	recruiting	290	Incyte Corporation	Dec 2023
NCT07617597	THRIVE-AAJP	Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata	P3	not yet recruiting	78	Sun Pharma Japan Limited	Jun 2026
NCT03117751		Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	P2/P3	active not recruiting	790	St. Jude Children's Research Hospital	Mar 2017
NCT07184853	RESCUE	Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD	N/A	recruiting	122	First Affiliated Hospital of Zhejiang University	Sep 2025
NCT06536166	BIGTIM	Ruxolitinib Treatment in Inclusion Body Myositis	P2	recruiting	80	Assistance Publique - Hôpitaux de Paris	May 2025
NCT05371964		A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis	P1	recruiting	36	Geron Corporation	May 2022
NCT04817007		A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)	P1/P2	active not recruiting	216	Bristol-Myers Squibb	Mar 2021
NCT06079879	BAT	A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)	P3	recruiting	340	Merck Sharp & Dohme LLC	Dec 2023
NCT06627335		An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis	—	recruiting	5,621	Incyte Corporation	Mar 2023
NCT03654768		Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia	P2	active not recruiting	81	SWOG Cancer Research Network	Oct 2018
NCT06859424	ACCELERATE	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation	P2	recruiting	358	Center for International Blood and Marrow Transplant Research	Jul 2025
NCT06364319		Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD	P4	not yet recruiting	118	Peking University People's Hospital	Apr 2024
NCT07025538		Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation	P1	recruiting	42	City of Hope Medical Center	Jun 2026
NCT07588945		daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT	P3	not yet recruiting	438	Institute of Hematology & Blood Diseases Hospital, China	Jun 2026
NCT07133308		Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata	P3	recruiting	355	Sun Pharmaceutical Industries, Inc.	Aug 2025
NCT05870475	PV	Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV	P2	recruiting	94	Institute of Hematology & Blood Diseases Hospital, China	Jun 2023
NCT05088356		Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	P1	active not recruiting	66	Stanford University	Sep 2021
NCT06832618	TRuE-AD5	A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis	P3	recruiting	240	Incyte Corporation	Jun 2025
NCT06909136		A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis	P1/P2	active not recruiting	33	Suzhou Junjing BioSciences Co., Ltd.	Jul 2025
NCT06150157	CALR	A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms	P1	recruiting	220	Janssen Research & Development, LLC	Dec 2023
NCT06936566	MAGIC V	MAGIC Ruxolitinib for aGVHD	P2	recruiting	98	John Levine	May 2025
NCT05762640	R-HLH	Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)	P2	recruiting	20	Assistance Publique - Hôpitaux de Paris	Nov 2024
NCT04562389	SENTRY	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis	P3	active not recruiting	353	Karyopharm Therapeutics Inc	Mar 2021
NCT07317700		A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis	P3	recruiting	105	Chengdu Zenitar Biomedical Technology Co., Ltd	Feb 2026
NCT05936359		A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	P1	recruiting	225	Incyte Corporation	Sep 2023
NCT06462469		Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease	P4	recruiting	36	Novartis Pharmaceuticals	Jul 2024
NCT07366801		Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies	P2/P3	recruiting	64	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Sep 2025
NCT06773195		A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis	P1/P2	recruiting	37	Memorial Sloan Kettering Cancer Center	Jan 2025
NCT03120624		VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	P1	active not recruiting	34	Mayo Clinic	Sep 2017
NCT07153666		A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo	—	recruiting	170	Peking University Third Hospital	Dec 2025
NCT06857240		Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis	P2	recruiting	15	The Cleveland Clinic	Jun 2025
NCT06199427		PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity	P2	recruiting	100	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Nov 2023
NCT04061421	ABNL-MARRO	Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)	P1/P2	recruiting	94	Michael Savona	Nov 2021
NCT03874052		Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	recruiting	51	Jennifer Saultz	Aug 2019
NCT07509749	GVHD	Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)	P2	recruiting	54	Daihong Liu	Jun 2025
NCT07576010		Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease	P1	active not recruiting	30	Daihong Liu	Jan 2025
NCT06804811		A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo	P3	recruiting	250	Incyte Corporation	Nov 2025
NCT05398809	APECED	Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata	P2	recruiting	70	National Institute of Allergy and Infectious Diseases (NIAID)	Jan 2023
NCT02974647		Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma	P2	recruiting	83	Memorial Sloan Kettering Cancer Center	Nov 2016
NCT06008808		Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	P1	recruiting	41	Washington University School of Medicine	May 2024
NCT04455841		INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders	P1/P2	active not recruiting	84	Incyte Corporation	Mar 2021
NCT06397313	POTAMI-61	RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis	P2	recruiting	230	Ryvu Therapeutics SA	Sep 2024
NCT04509700	INCB050465	Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)	P2	active not recruiting	112	Incyte Corporation	Aug 2020
NCT02955940		An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib	P2	active not recruiting	10	Incyte Corporation	Nov 2016
NCT02386800		CINC424A2X01B Rollover Protocol	P4	active not recruiting	279	Novartis Pharmaceuticals	Mar 2015
NCT03571321		Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia	P1	recruiting	15	University of Chicago	May 2019
NCT05010005		A Study of Ruxolitinib and Duvelisib in People With Lymphoma	P1	recruiting	70	Memorial Sloan Kettering Cancer Center	Aug 2021
NCT03681561		Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma	P1/P2	recruiting	54	Veronika Bachanova	Sep 2018
NCT06959225		Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)	P3	recruiting	550	Incyte Corporation	Jun 2025
NCT06958211		Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)	P3	recruiting	550	Incyte Corporation	Jun 2025
NCT04603495	MANIFEST-2	Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)	P3	active not recruiting	430	Novartis Pharmaceuticals	Apr 2021
NCT07249346	GVHD	Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation	P2	recruiting	124	Hannah Choe, MD	Jun 2026
NCT07340723	GVHD	Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )	P2	recruiting	168	Daihong Liu	Jun 2025
NCT06225310	KPT-IST-391	A Trial of Selinexor, Ruxolitinib and Methylprednisolone	P1	recruiting	30	Oncotherapeutics	Aug 2024
NCT05280509		Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib	P1/P2	recruiting	70	Telios Pharma, Inc.	Jun 2022
NCT04279847	LIMBER	Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms	P1	active not recruiting	140	Incyte Corporation	Feb 2021
NCT07278856		Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas	P1	recruiting	20	City of Hope Medical Center	Dec 2025
NCT04328844	IOA-244	A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers	P1	active not recruiting	210	iOnctura	Feb 2020
NCT06548360		A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo	P3	recruiting	180	Incyte Corporation	Jan 2025
NCT00044304		Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome	P2	active not recruiting	70	National Institute of Allergy and Infectious Diseases (NIAID)	Sep 2002
NCT03069326		A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis	P2	active not recruiting	30	Memorial Sloan Kettering Cancer Center	Feb 2017
NCT03110822	RRMM	A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	P1	recruiting	134	Oncotherapeutics	Feb 2017
NCT03954236		Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease	P2	active not recruiting	24	Memorial Sloan Kettering Cancer Center	May 2019
NCT07356245		Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma	P2	recruiting	44	Jonathan Brammer	Feb 2026
NCT05714072		A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis	P1	recruiting	18	Memorial Sloan Kettering Cancer Center	Jan 2023
NCT04454658		Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis	P1	active not recruiting	21	AbbVie	Nov 2020
NCT06008275		Neratinib in Combination With Ruxolitinib in Patients With mTNBC	Early P1	recruiting	20	Baylor Research Institute	Sep 2024
NCT06573593		Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	recruiting	150	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jul 2024
NCT04468984	TRANSFORM-2	Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis	P3	active not recruiting	330	AbbVie	Aug 2020
NCT04217356	ALLO-BAT	Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis	—	active not recruiting	90	University Health Network, Toronto	Aug 2020
NCT04041050		A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm	P1	active not recruiting	85	AbbVie	Nov 2019
NCT03286530		Ruxolitinib + Allogeneic Stem Cell Transplantation in AML	P2	active not recruiting	64	Massachusetts General Hospital	Nov 2017
NCT05817955		Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN	P2	recruiting	50	The First Affiliated Hospital with Nanjing Medical University	Nov 2022
NCT07238712	APTBCy	Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor	P2	recruiting	60	St. Petersburg State Pavlov Medical University	May 2025
NCT07049575		Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa	P1	recruiting	24	Incyte Corporation	Nov 2025
NCT04282187		Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms	P2	recruiting	25	University of Washington	Mar 2020
NCT03610971		Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors	P2	active not recruiting	24	H. Lee Moffitt Cancer Center and Research Institute	Nov 2019
NCT06607367	RESELECT2	REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2	P1/P2	not yet recruiting	20	Melbourne Health	Oct 2024
NCT06752694		Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia	P2	active not recruiting	1	Fred Hutchinson Cancer Center	Sep 2025
NCT06664970		A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor	P2	enrolling by invitation	39	Peking Union Medical College Hospital	Nov 2024
NCT06075225		MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib	P2	not yet recruiting	62	Sichuan University	Oct 2023
NCT05622318	GVHD	De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis	P2	active not recruiting	56	Medical College of Wisconsin	Aug 2023
NCT02131584		Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia	P2	active not recruiting	10	M.D. Anderson Cancer Center	Sep 2014
NCT07588139		A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants	P1	recruiting	24	Incyte Corporation	May 2026
NCT04551131		Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis	P1/P2	active not recruiting	10	St. Jude Children's Research Hospital	Jul 2021
NCT05909943		Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders	P1/P2	withdrawn	0	Tianjin Medical University General Hospital	Jun 2024
NCT05592015		Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia	P2	recruiting	30	Jonathan Brammer	May 2023
NCT06457425		A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis	P2	recruiting	75	Chengdu Zenitar Biomedical Technology Co., Ltd	May 2024
NCT02494882		Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older	P1	active not recruiting	12	Memorial Sloan Kettering Cancer Center	Jun 2015
NCT03722407	CMML	Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion	P2	active not recruiting	29	H. Lee Moffitt Cancer Center and Research Institute	Aug 2019
NCT06399029	TRUX-LST	Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities	P2	active not recruiting	22	University of Zurich	Oct 2024
NCT06291987	MPN	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	P1	recruiting	18	University of Chicago	Sep 2024
NCT02876302	INCB018424	Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer	P2	active not recruiting	23	Dana-Farber Cancer Institute	Jan 2018
NCT02723994		A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	P2	completed	171	Incyte Corporation	Sep 2016
NCT06261021		Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus	P2	recruiting	20	Innovaderm Research Inc.	Apr 2024
NCT05123040		Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids	P1/P2	terminated	10	Masonic Cancer Center, University of Minnesota	Jun 2023
NCT06244862	JAKAHDI	JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit	P2	unknown	42	Assistance Publique - Hôpitaux de Paris	Feb 2024
NCT06719024	RCT	Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus	P2/P3	recruiting	20	Hospital Authority, Hong Kong	Nov 2024
NCT02251821		JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis	P2	completed	61	Fred Hutchinson Cancer Center	Oct 2014
NCT01787487		Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm	P2	completed	121	M.D. Anderson Cancer Center	Mar 2013
NCT07368673		Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial	P4	completed	120	Dow University of Health Sciences	Apr 2025
NCT05491304		Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis	P4	unknown	400	The Children's Hospital of Zhejiang University School of Medicine	Sep 2022
NCT04906746		Ruxolitinib for Cancer Cachexia	Early P1	active not recruiting	10	Tu Dan	Feb 2022
NCT03674047	BOS	Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)	P2	active not recruiting	50	Massachusetts General Hospital	Apr 2019
NCT05599256		Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model	P2	unknown	40	Institute of Hematology & Blood Diseases Hospital, China	Feb 2023
NCT04908735	HSCT	Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant	P2	terminated	7	Children's Hospital Medical Center, Cincinnati	Nov 2021
NCT05764161	TRuE-PN2	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)	P3	completed	190	Incyte Corporation	Jun 2023
NCT06238817	TRuE-AD4	A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis	P3	completed	241	Incyte Corporation	Apr 2024
NCT03333187		Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability	P2	active not recruiting	87	Universitätsklinikum Hamburg-Eppendorf	Dec 2016
NCT06923228		A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis	P2	completed	3	CAGE Bio Inc.	Apr 2025
NCT04582604		Ruxolitinib and Decitabine for High Risk Hematological Malignancies	P1/P2	unknown	60	Chinese PLA General Hospital	Sep 2020
NCT06695507		Upfront Ruxolitinib for Chronic Graft-vs-host Disease	P1	terminated	1	Children's Hospital Medical Center, Cincinnati	Feb 2025
NCT05755438	TRuE-PN1	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)	P3	completed	204	Incyte Corporation	Mar 2023
NCT06213831		A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream	P1	completed	23	Incyte Corporation	Feb 2024
NCT05899725		The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia	N/A	unknown	60	Peking Union Medical College Hospital	Apr 2023
NCT05762874		Ruxolitinib in Patients With Myelofibrosis	—	unknown	51	Assiut University	Mar 2023
NCT05075681		Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma	P1/P2	unknown	50	Chinese PLA General Hospital	Nov 2021
NCT05440942		Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma	P1	completed	28	Peter Hosein, MD	Jan 2023
NCT03427866		Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.	P2	completed	44	Massachusetts General Hospital	Aug 2018
NCT06619522		A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis	P2	withdrawn	0	M.D. Anderson Cancer Center	Sep 2024
NCT05914714		Ruxolitinib as GVHD Prophylaxis in AA Patients	P2	unknown	46	Institute of Hematology & Blood Diseases Hospital, China	Jul 2023
NCT04669210	PTCyRuxo	PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT	P2	completed	128	St. Petersburg State Pavlov Medical University	Nov 2020
NCT05750823		A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo	P2	completed	49	Incyte Corporation	Apr 2023
NCT05998395		JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease	P1/P2	completed	1	National Heart, Lung, and Blood Institute (NHLBI)	Sep 2023
NCT03878199		Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms	P1/P2	terminated	12	Ohio State University Comprehensive Cancer Center	Feb 2019
NCT04472598	TRANSFORM-1	Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis	P3	completed	252	AbbVie	Sep 2020
NCT03222609	REFINE	A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis	P2	completed	191	AbbVie	Oct 2017
NCT05696392	MORPHEUS	The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.	P4	terminated	47	Incyte Corporation	Mar 2023
NCT05872477	PREVENT	Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas	P2	completed	20	Centre Hospitalier Universitaire de Nice	Sep 2023
NCT02158858		A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies	P1/P2	completed	336	Constellation Pharmaceuticals	Jul 2014
NCT05413356		Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome	P2	unknown	50	First Affiliated Hospital of Zhejiang University	Jun 2022
NCT05293717		Topical Ruxolitinib in Chronic Hand Dermatitis	P1/P2	completed	16	University of Rochester	Jul 2022
NCT05906628		Topical Ruxolitinib Evaluation in Chronic Hand Eczema	P2	completed	186	Incyte Corporation	Jul 2023
NCT05600855		Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model	P2	completed	115	Institute of Hematology & Blood Diseases Hospital, China	Jan 2023
NCT04838704		Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation	N/A	completed	215	Zhejiang University	Apr 2021
NCT04269850	JAK-FMT	Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD	P1/P2	terminated	2	St. Petersburg State Pavlov Medical University	Sep 2019
NCT04551066	LIMBER-313	To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)	P3	terminated	252	Incyte Corporation	May 2021
NCT06555081	XR	A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants	P1	completed	168	Incyte Corporation	Sep 2024
NCT04485260	PMF	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib	P1/P2	unknown	36	Kartos Therapeutics, Inc.	Jan 2021
NCT06673654		A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.	P1	completed	476	Sun Pharmaceutical Industries, Inc.	Aug 2023
NCT05219864	TRuE-CHE1	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1	P3	withdrawn	0	Incyte Corporation	Jan 2023
NCT05233410	TRuE-CHE2	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2	P3	withdrawn	0	Incyte Corporation	Jan 2023
NCT03701698		Ruxolitinib and Steroid As First Line Therapy for Acute GVHD	P2	terminated	1	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Nov 2018
NCT02928978	TBCRC042	Ruxolitinib for Premalignant Breast Disease	P2	completed	84	Julie Nangia	May 2018
NCT03558607		The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm	P1/P2	unknown	17	Seoul National University Hospital	May 2018
NCT04097821	ADORE	Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients	P1/P2	terminated	45	Novartis Pharmaceuticals	Sep 2019
NCT04551053	LIMBER-304	To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)	P3	terminated	177	Incyte Corporation	May 2021
NCT05566535	QoL-PV-R	Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice	—	unknown	32	Multinational Center for Quality of Life Research, Russia	Oct 2022
NCT04999878	RUE-DDGP	A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.	P4	unknown	30	Zhengzhou University	May 2021
NCT05137496		Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome	P3	unknown	40	Beijing Friendship Hospital	Jun 2022
NCT02493530		TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea	P1	completed	60	Vanderbilt-Ingram Cancer Center	Jul 2015
NCT02713386		Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P1/P2	completed	147	NRG Oncology	Nov 2016
NCT05456529		Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis	P3	completed	103	Incyte Corporation	Sep 2022
NCT06310304	XR	A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.	P1	completed	24	Incyte Corporation	Mar 2024
NCT05579769		Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.	P2	terminated	3	St. Jude Children's Research Hospital	Mar 2023
NCT04921969		A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)	P3	completed	330	Incyte Corporation	Jul 2021
NCT04303403		Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma	P1	unknown	48	National Cancer Centre, Singapore	Jul 2018
NCT05635838		Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa	P2	completed	69	Incyte Corporation	Dec 2022
NCT04908280		Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus	P2	completed	10	University of Rochester	May 2022
NCT05593432		A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus	P2	completed	64	Incyte Corporation	Nov 2022
NCT04414514		Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment	P2	terminated	6	Milton S. Hershey Medical Center	Oct 2022
NCT03773107	MMRC-073 CARJAK	LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma	P1/P2	completed	12	Wake Forest University Health Sciences	Jan 2019
NCT05787860		Ruxolitinib in Seborrheic Dermatitis	P2	completed	45	Icahn School of Medicine at Mount Sinai	Nov 2022
NCT02784496		Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis	P2	completed	8	M.D. Anderson Cancer Center	Sep 2016
NCT04218071		Actuate 1901: 9-ING-41 in Myelofibrosis	P2	completed	17	Actuate Therapeutics Inc.	Aug 2020
NCT02638428		Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy	P2	unknown	90	Samsung Medical Center	Dec 2015
NCT05593445		A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus	P2	completed	61	Incyte Corporation	Nov 2022
NCT05247489		A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo	P2	completed	55	Incyte Corporation	May 2022
NCT05447260		A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis	P4	unknown	87	Qilu Hospital of Shandong University	Jun 2022
NCT03153982		Ruxolitinib in Operable Head and Neck Cancer	P2	terminated	16	University of California, San Francisco	Jun 2018
NCT04807777		Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma	P2	terminated	3	Columbia University	Apr 2022
NCT05127421		Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement	P2	completed	77	Incyte Corporation	Nov 2021
NCT04581954	MATIS	Inflammatory Signal Inhibitors for COVID-19 (MATIS)	P1/P2	completed	185	Imperial College London	Oct 2020
NCT02917096		Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis	P1	completed	18	City of Hope Medical Center	Nov 2016
NCT05034822		Study of Ruxolitinib Cream in Children With Atopic Dermatitis	P1	completed	29	Incyte Corporation	Dec 2021
NCT04480086		Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis	P1	terminated	1	AbbVie	Mar 2021
NCT04896385		A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)	P2	completed	60	Incyte Corporation	Jun 2021
NCT04061876		First Line Therapy for High Risk Acute GVHD	P2	completed	198	Chinese PLA General Hospital	Aug 2019
NCT04354727		A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy	P1/P2	withdrawn	0	Ascentage Pharma Group Inc.	Dec 2020
NCT03616184		Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids	P2	completed	49	University of Nebraska	Sep 2018
NCT04281498		Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation	P2	completed	6	John Mascarenhas	Jan 2021
NCT05121142		Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease	P1	completed	13	Children's Hospital Medical Center, Cincinnati	Oct 2021
NCT03012230		Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	P1	completed	12	Mayo Clinic	Dec 2017
NCT05722912		Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD	—	approved for marketing	0	Incyte Corporation	—
NCT03491215		Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease	P1/P2	completed	45	Novartis Pharmaceuticals	Feb 2019
NCT04934670	2002	A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)	P3	terminated	12	Xenikos	Jun 2022
NCT05021276		Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD	P4	unknown	50	The First Affiliated Hospital of Soochow University	Dec 2020
NCT03112603	BAT	A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)	P3	completed	330	Incyte Corporation	Jun 2017
NCT05663827		Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease	P3	completed	6	Yi-Lun Wang	Jan 2019
NCT04839380	SCRATCH-AD	The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis	P2	completed	49	Incyte Corporation	Oct 2021
NCT04530344		Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo	P3	completed	458	Incyte Corporation	Sep 2020
NCT04424056	INFLAMMACOV	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease	P3	unknown	216	Assistance Publique Hopitaux De Marseille	Sep 2020
NCT03669965		KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera	P2	unknown	20	Kartos Therapeutics, Inc.	Jan 2019
NCT04055844		Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS	P2	completed	14	Masonic Cancer Center, University of Minnesota	Feb 2020
NCT04543279		Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia	P2	terminated	3	Washington University School of Medicine	May 2021
NCT02152956	VOYAGE	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	P1/P2	terminated	244	MacroGenics	Jun 2014
NCT05052385		ECP Combination Study	—	completed	319	European Society for Blood and Marrow Transplantation	Apr 2021
NCT01712308		Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia	P2	completed	56	M.D. Anderson Cancer Center	Feb 2013
NCT01776723		A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib	P1/P2	completed	50	H. Lee Moffitt Cancer Center and Research Institute	Feb 2013
NCT02718300		A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis	P2	terminated	74	Incyte Corporation	Feb 2017
NCT04492618		Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica	P2	completed	12	Aaron R. Mangold	Sep 2020
NCT05269771		MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera	—	no longer available	0	Novartis Pharmaceuticals	—
NCT03795909		Ruxolitinib Combined With Dexamethasone for HLH	P1/P2	unknown	50	Capital Research Institute of Pediatrics	Mar 2017
NCT01712659		Ruxolitinib for Adult T-Cell Leukemia	P1/P2	terminated	19	National Cancer Institute (NCI)	Oct 2012
NCT04354714		Ruxolitinib to Combat COVID-19	P2	withdrawn	0	Washington University School of Medicine	Jun 2020
NCT04016116		Dual PD-1 and JAK2 Inhibition in Hematological Malignancies	P2	withdrawn	0	NYU Langone Health	Dec 2019
NCT03959371		Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy	—	unknown	620	Margherita Maffioli	Apr 2017
NCT05410470		Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis	—	completed	130	Qilu Hospital of Shandong University	Aug 2012
NCT04348071		Safety and Efficacy of Ruxolitinib for COVID-19	P2/P3	withdrawn	0	University of Colorado, Denver	Jul 2021
NCT04052425		Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)	P3	completed	330	Incyte Corporation	Sep 2019
NCT03386214		Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis	P1	terminated	8	Washington University School of Medicine	Apr 2018
NCT04057573		Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)	P3	completed	344	Incyte Corporation	Oct 2019
NCT03514069		Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma	P1	completed	60	Case Comprehensive Cancer Center	Jun 2018
NCT03099304		A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo	P2	completed	157	Incyte Corporation	Jun 2017
NCT02973711		A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML	P1/P2	withdrawn	0	University of Michigan Rogel Cancer Center	Jan 2018
NCT04359290	RuXoCoil	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	P2	completed	15	Philipps University Marburg	Jul 2020
NCT04338958	RuxCoFlam	Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation	P2	completed	193	University of Jena	Apr 2020
NCT02962388		The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line	P2/P3	terminated	13	French Innovative Leukemia Organisation	Jan 2017
NCT02613598		Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma	P1	completed	15	University of Michigan Rogel Cancer Center	May 2016
NCT03144687		A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis	P2	completed	23	Incyte Corporation	Jan 2018
NCT04446806		Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia	P4	unknown	100	The First Affiliated Hospital of Soochow University	Jun 2019
NCT01431209		Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant	P2	completed	71	University of Nebraska	Aug 2011
NCT04334044		Treatment of SARS Caused by COVID-19 With Ruxolitinib	P1/P2	completed	77	Grupo Cooperativo de Hemopatías Malignas	Sep 2020
NCT02913261	REACH2	Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation	P3	completed	310	Novartis Pharmaceuticals	Mar 2017
NCT03613428		Ruxolitinib Plus LVP in Patients With R/R ETP-ALL	P1/P2	unknown	12	Sichuan University	Dec 2018
NCT04477993	RUXO-COVID	Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19	P2/P3	terminated	5	Vanderson Geraldo Rocha	Aug 2020
NCT04331665		Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia	N/A	terminated	3	University Health Network, Toronto	May 2020
NCT02257138		Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia	P1/P2	completed	30	M.D. Anderson Cancer Center	Feb 2015
NCT04377620	RUXCOVID-DEVENT	Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)	P3	terminated	211	Incyte Corporation	May 2020
NCT04745637		Managed Access Programs for INC424, Ruxolitinib	—	available	0	Novartis Pharmaceuticals	—
NCT04348695	Ruxo-Sim-20	Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.	P2	completed	94	Fundación de investigación HM	Apr 2020
NCT02041429		Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca	P1/P2	completed	20	Dana-Farber Cancer Institute	Feb 2014
NCT02420717		Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	P2	terminated	11	M.D. Anderson Cancer Center	Jul 2015
NCT04397367		Low Dose Ruxolitinib in Combination With Methylprednisolone	P1/P2	completed	38	Chinese PLA General Hospital	Jan 2019
NCT03878524	SMMART	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	P1	terminated	2	OHSU Knight Cancer Institute	Apr 2020
NCT04374149		Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS	P2	completed	20	Prisma Health-Upstate	Apr 2020
NCT03745638		Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis	P3	completed	631	Incyte Corporation	Dec 2018
NCT04456634		Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine	P1	completed	8	Medicines for Malaria Venture	Sep 2020
NCT03745651		TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis	P3	completed	618	Incyte Corporation	Dec 2018
NCT02370706	INC424	Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis	P1	completed	15	Novartis Pharmaceuticals	May 2015
NCT04362137	RUXCOVID	Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm	P3	completed	432	Novartis Pharmaceuticals	May 2020
NCT02066532		Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	P1/P2	completed	32	Dawn L. Hershman	Jun 2014
NCT03257644		A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis	P1	completed	70	Incyte Corporation	Sep 2017
NCT04366232	JAKINCOV	Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation	P2	terminated	2	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Aug 2020
NCT04414098		Ruxolitinib in the Treatment of Covid-19	P2	unknown	100	Marcelo Iastrebner	Jun 2020
NCT04403243	COLORIT	COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19	P2	completed	70	Lomonosov Moscow State University Medical Research and Educational Center	May 2020
NCT02587598		Study of INCB053914 in Subjects With Advanced Malignancies	P1/P2	terminated	97	Incyte Corporation	Dec 2015
NCT03123588	RESET-272	Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)	P2	terminated	12	Incyte Corporation	Nov 2017
NCT03515200		Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia	P1	terminated	12	St. Jude Children's Research Hospital	Apr 2018
NCT01981850		A Phase 2 Study of RO7490677 In Participants With Myelofibrosis	P2	completed	125	Hoffmann-La Roche	Oct 2013
NCT04120090		Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis	P3	unknown	80	Beijing Friendship Hospital	Jul 2019
NCT01433445		Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	P1	completed	61	Novartis Pharmaceuticals	Nov 2011
NCT04361903	RESPIRE	Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection	—	unknown	13	Azienda USL Toscana Nord Ovest	Apr 2020
NCT03041636		Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P2	completed	1	M.D. Anderson Cancer Center	Mar 2017
NCT04355793		Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection	—	no longer available	0	Incyte Corporation	—
NCT02038036	RESPONSE-2	Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.	P3	completed	149	Novartis Pharmaceuticals	Mar 2014
NCT04337359	MAP	Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness	—	no longer available	0	Novartis Pharmaceuticals	—
NCT03274778		Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells	N/A	withdrawn	0	Oncology Institute of Southern Switzerland	Sep 2017
NCT03373877		Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis	P1	terminated	4	Samus Therapeutics, Inc.	May 2018
NCT02092324		Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	P2	completed	51	OHSU Knight Cancer Institute	Jul 2014
NCT02400463		A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome	P2	completed	6	University of Michigan Rogel Cancer Center	Feb 2016
NCT01317875	PMF	Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)	P1	completed	69	Incyte Corporation	Mar 2011
NCT03920852		A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis	P1	completed	41	Incyte Corporation	May 2019
NCT01751425		Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors	P1	terminated	8	M.D. Anderson Cancer Center	Jul 2013
NCT02912754		Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients	P1/P2	unknown	36	Sunnybrook Health Sciences Centre	Mar 2017
NCT02953678	REACH-1	A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)	P2	completed	71	Incyte Corporation	Dec 2016
NCT02164500	JeRiCHO	JAK-inhibition in Recurrent Classical Hodgkin Lymphoma	P2	completed	12	University of Cologne	Oct 2015
NCT01969838	Simplify 1	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis	P3	completed	432	Sierra Oncology LLC - a GSK company	Dec 2013
NCT02997280		Ruxolitinib for Steroid-refractory GVHD	P2	completed	75	St. Petersburg State Pavlov Medical University	Aug 2016
NCT02806375		PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis	P1/P2	completed	20	St. Petersburg State Pavlov Medical University	Jan 2016
NCT01895842	MDS	Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)	P1	completed	31	M.D. Anderson Cancer Center	Feb 2014
NCT02966353	REALISE	Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.	P2	completed	51	Novartis Pharmaceuticals	Mar 2017
NCT02711137		Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies	P1/P2	terminated	137	Incyte Corporation	May 2016
NCT03395340		Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)	P2	terminated	1	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Nov 2018
NCT01702064	CML	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients	P1	completed	11	H. Lee Moffitt Cancer Center and Research Institute	Feb 2013
NCT01914484		Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	P1/P2	completed	4	University Health Network, Toronto	Aug 2013
NCT01348490	INCB018424	Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)	P2	completed	66	Incyte Corporation	Jun 2011
NCT02072057		Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.	P2	terminated	8	Kantonsspital Aarau	Apr 2014
NCT02779283		Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia	P1	completed	7	OHSU Knight Cancer Institute	Jan 2016
NCT01965119	JAK2	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma	P2	completed	20	Samsung Medical Center	Nov 2013
NCT01375140		Ruxolitinib and Lenalidomide for Patients With Myelofibrosis	P2	completed	31	M.D. Anderson Cancer Center	Sep 2011
NCT00726232		Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia	P2	terminated	73	Incyte Corporation	Aug 2008
NCT02076191		Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	P1/P2	completed	49	John Mascarenhas	Feb 2014
NCT01877005	HIJAK	A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma	P2	completed	33	The Lymphoma Academic Research Organisation	Jul 2013
NCT02267278	MF	Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)	P2	completed	25	M.D. Anderson Cancer Center	Jan 2015
NCT01693601	PRIME	Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)	P1/P2	completed	15	John Mascarenhas	Jan 2013
NCT02475655		Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults	P2	completed	60	National Institute of Allergy and Infectious Diseases (NIAID)	May 2016
NCT02253277	CoRNea	Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients	P1	completed	5	Novartis Pharmaceuticals	Feb 2015
NCT03011892		A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis	P2	completed	307	Incyte Corporation	Jan 2017
NCT01243944	INCB018424	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	P3	completed	222	Incyte Corporation	Oct 2010
NCT02292446	ETP	Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.	P3	completed	161	Novartis Pharmaceuticals	Nov 2014
NCT02436135	Madison	Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease	P1	terminated	10	Gilead Sciences	Jun 2015
NCT02145637	NSCLC	Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)	P1	completed	30	Yonsei University	May 2015
NCT02155465		Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib	P1/P2	completed	22	Memorial Sloan Kettering Cancer Center	Jun 2014
NCT01392443	MF	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF	P2	completed	120	Novartis Pharmaceuticals	Oct 2010
NCT01790295		Ruxolitinib Prior to Transplant in Patients With Myelofibrosis	P2	terminated	21	John Mascarenhas	Nov 2013
NCT02598297	ReTHINK	Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.	P3	terminated	49	Novartis Pharmaceuticals	Feb 2016
NCT02553330	AA	A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)	P2	terminated	90	Incyte Corporation	Nov 2015
NCT01732445		Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis	P2	completed	14	Mayo Clinic	Apr 2013
NCT02593760	MF	A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)	P1	completed	10	Hoffmann-La Roche	Jan 2016
NCT03147742		An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant	—	approved for marketing	0	Incyte Corporation	—
NCT01620216		Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	P2	terminated	12	OHSU Knight Cancer Institute	May 2012
NCT02809976		Topical Ruxolitinib for the Treatment of Vitiligo	P2	completed	11	Tufts Medical Center	Jan 2016
NCT00509899	INCB018424	Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis	P1/P2	completed	154	Incyte Corporation	Jun 2007
NCT02593929		Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer	Early P1	withdrawn	0	University of Pittsburgh	Jan 2017
NCT02120417		A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer	P2	terminated	149	Incyte Corporation	May 2014
NCT02117479		Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)	P3	terminated	321	Incyte Corporation	Mar 2014
NCT02119676		Study of Ruxolitinib in Colorectal Cancer Patients	P2	terminated	396	Incyte Corporation	Mar 2014
NCT01423604	RECAP	Study of Ruxolitinib in Pancreatic Cancer Patients	P2	completed	136	Incyte Corporation	Jul 2011
NCT02119663		A Study of Ruxolitinib in Pancreatic Cancer Patients	P3	terminated	86	Incyte Corporation	Jun 2014
NCT02469974		Ruxolitinib in Combination With Autotransplant	N/A	withdrawn	0	Marina Kremyanskaya	May 2015
NCT01822756		An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors	P1	terminated	42	Incyte Corporation	Apr 2013
NCT01562873		Ruxolitinib in Patients With Breast Cancer	P2	terminated	21	Dana-Farber Cancer Institute	Jun 2012
NCT02119650		Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer	P2	terminated	76	Incyte Corporation	Feb 2014
NCT01632904		Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study	P3	completed	110	Incyte Corporation	Jun 2012
NCT01950780		Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata	P2	completed	12	Columbia University	Aug 2013
NCT02049450		Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.	P2	completed	30	Novartis Pharmaceuticals	May 2014
NCT01594216		Ruxolitinib in Estrogen Receptor Positive Breast Cancer	P2	completed	25	Abramson Cancer Center at Penn Medicine	Apr 2012
NCT02528877		Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	P1	withdrawn	0	City of Hope Medical Center	Nov 2015
NCT00952289		COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial	P3	completed	309	Incyte Corporation	Aug 2009
NCT02015208		Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia	P1/P2	completed	13	Sunnybrook Health Sciences Centre	Apr 2014
NCT02087059	PM	A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis	P3	completed	51	Novartis Pharmaceuticals	Apr 2014
NCT00934544	JAK	Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial	P3	completed	219	Novartis Pharmaceuticals	Jul 2009
NCT02091752		A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)	P2	terminated	3	Novartis Pharmaceuticals	Sep 2014
NCT01369498		Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis	P2	completed	54	Gilead Sciences	Jun 2011
NCT01445769		Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	P2	completed	45	Incyte Corporation	Sep 2011
NCT01730755		Ruxolitinib for Chuvash Polycythemia	—	no longer available	0	Washington University School of Medicine	—
NCT01340651	INCB018424	Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients	P2	completed	41	Incyte Corporation	Mar 2011
NCT01251965		Phase l/II Study of Ruxolitinib for Acute Leukemia	P1/P2	terminated	27	M.D. Anderson Cancer Center	Dec 2010
NCT01164163		INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease	P1	completed	49	Children's Oncology Group	Sep 2010
NCT00639002	JAK2	A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma	P2	completed	13	Incyte Corporation	Mar 2008
NCT00778700		A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis	P2	completed	199	Incyte Corporation	Oct 2008
NCT00617994		Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis	P2	completed	25	Incyte Corporation	Aug 2007
NCT00820950		A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis	P2	completed	29	Incyte Corporation	May 2007
NCT00638378	INCB018424	Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer	P2	terminated	22	Incyte Corporation	Feb 2008

Ruxolitinib clinical trials: frequently asked questions

How many Ruxolitinib clinical trials are there?: 388 Ruxolitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 95 are actively recruiting participants. 138 are marked completed.
Are Ruxolitinib clinical trials recruiting in 2026?: Yes — 95 Ruxolitinib trials are actively recruiting in 2026, with 558 U.S. sites across 41 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ruxolitinib being studied for?: Ruxolitinib is being studied for Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Atopic Dermatitis, Vitiligo and 493 more. The trials are grouped by indication on this page.
What phase is Ruxolitinib in?: Ruxolitinib clinical trials span 14 Phase 4, 53 Phase 3, 158 Phase 2, 69 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ruxolitinib clinical trials?: The lead sponsor across the most Ruxolitinib trials is Incyte Corporation, with 159 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ruxolitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Ruxolitinib overview Ruxolitinib evidence & publications